

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Diagnostic Accuracy of Image Technique Based Transurethral Resection for Non-muscle Invasive Bladder Cancer

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028173
Article Type:	Research
Date Submitted by the Author:	25-Nov-2018
Complete List of Authors:	Chen, Changhao; Sun Yat-Sen Memorial Hospital, Department of Urology Huang, Hao; Sun Yat-Sen Memorial Hospital, Department of Urology Zhao, Yue; the First Affiliated Hospital of Sun Yat-Sen University, Department of Gastroenterology Liu, Hao; Chengdu Fifth People's Hospital, Department of Urology Sylvester, Richard; EAU Guidelines Office, Brussels Lin, Tianxin; Sun Yat-Sen Memorial Hospital, Department of Urology Huang, Jian; Sun Yat-Sen Memorial Hospital, Department of Urology
Keywords:	bladder cancer, diagnostic performance, Narrow band imaging, photodynamic diagnosis, white light-guided cystoscopy

SCHOLARONE™  
Manuscripts

11 **Diagnostic Accuracy of Image Technique Based Transurethral Resection for Non-muscle Invasive**  
12  
13  
14 **Bladder Cancer**

15 Changhao Chen<sup>1,2#</sup>; Hao Huang<sup>1,2#</sup>; Yue Zhao<sup>3#</sup>; Hao Liu<sup>4</sup>; Richard J. Sylvester<sup>5</sup>; Tianxin Lin<sup>1,2\*</sup>; Jian  
16  
17 Huang<sup>1,2\*</sup>

18 <sup>1</sup>Department of Urology, <sup>2</sup>Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene  
19 Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong, P. R. China

20 <sup>3</sup> Department of Interventional Oncology, Sun Yat-Sen University First Affiliated Hospital, Guangzhou,  
21  
22 China;

23 <sup>4</sup>Department of Urology, Chengdu Fifth People's Hospital, Chengdu, P. R. China

24 <sup>5</sup>European Association of Urology Guidelines Office, Arnhem, Netherlands

25  
26  
27 #These authors contributed equally to this study.

28  
29  
30 \*Corresponding authors, to whom requests for reprints should be addressed.

31  
32  
33 Jian Huang MD, PhD

34  
35  
36 Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yan-Jiang Xi Road,  
37  
38 Guangzhou, 510120, China

39  
40  
41 Tel. +86 20 81332603; Fax: +86 20 81332853.

42  
43  
44 E-mail address: [urolhj@sina.com](mailto:urolhj@sina.com)

45  
46  
47 Tianxin Lin MD, PhD

48  
49  
50 Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yan-Jiang Xi Road,  
51  
52 Guangzhou, 510120, China

53  
54  
55 Tel. +86 20 81332603; Fax: +86 20 81332853.

56  
57  
58 E-mail address: [tianxinl@sina.com](mailto:tianxinl@sina.com)

## Abstract

**Objective** To explore diagnostic accuracy of image technique based transurethral resection for bladder cancer, with white light-guided cystoscopy (WLC) as reference standard.

**Design** Systematic review and meta-analysis.

**Data sources** PubMed/MEDLINE, Web of Science, the Cochrane Library, Central Register of Controlled Trials and Embase from inception through 31<sup>st</sup> March 2018.

**Methods** We included studies reporting diagnostic performance of PDD with 5-ALA, PDD with HAL, or NBI, with WLC as reference standard in patient or lesion level. Study risk of bias was assessed using the Quality Assessment of Diagnostic Studies-2 (QUADAS-2). We pooled data using random-effect diagnostic meta-analysis and relevant sensitivity analyses were undertaken.

**Results:** 26 studies recruiting a total of 3979 patients were identified in this diagnostic meta-analysis.

Pooled sensitivity (SSY), specificity (SPY), diagnostic odds ratio (DOR) and area under the receiver operating characteristic curve (AUROC) values were calculated per groups of NBI, HAL and 5-ALA in lesions or patient level. NBI showed significant diagnostic superiority compared with WLC in lesion level (SSY 0.94, 95% CI, 0.82-0.98; SPY 0.79, 95% CI, 0.73-0.85; DOR 40.09, 95% CI, 20.08-80.01; AUROC 0.88, 95% CI, 0.85-0.91). The DOR for NBI showed highest (358.71, 95% CI, 44.50-2891.71) in patient level. Sensitivity analyses were performed on studies with low to moderate RoB and at least 100 patients at lesion level. These results showed consistency with those obtained in our overall analysis.

**Conclusions** Pooled data indicates image technique based transurethral resection (NBI, HAL and 5-ALA) show diagnostic superiority than WLC. Moreover, NBI could potentially be the most promising diagnostic intervention with best diagnostic accuracy outcomes. Novel Imaging technologies still need to compete with the diagnostic and prognostic outcome of WLC while offering advantages in terms of cost, and reliability.

**Key words:** bladder cancer, diagnostic performance, Narrow band imaging, photodynamic diagnosis, white light-guided cystoscopy

### Strengths and limitations of this study

- This is the first systematic review and diagnostic meta-analysis exploring diagnostic accuracy of image technique based transurethral resection compared with WLC.
- Our study include the stringent methodology used to synthesize the evidence obtained, such as adhering to PRISMA guidelines, using standardized definitions of diagnostic performance analysis and applying QUADAS-2 tool for RoB assessment.
- The majority of studies had a low or moderate risk of bias. All studies clearly reported methodology for the index test and reference standard, and were not considered a significant source of potential bias.
- The further sensitivity analysis was based on relatively few studies, but we used random-effect models to compensate for clinical and methodological diversity among studies.
- The lack of data on important clinical variables, such as grade and stage of disease, primary vs recurrent disease and intravesical instillation settings, may introduce clinical heterogeneity and prevent further sensitivity analyses. We attempted to minimize biases by standardizing data extraction and performing several sensitivity analyses.

## Introduction

Bladder cancer is a prevalent malignancy with an estimated 166,583 newly diagnosed cases and 58,742 deaths in Europe in 2012, among which about 75% of patients present with non-muscle invasive bladder cancer (NMIBC) <sup>1-3</sup>. Today, white light cystoscopy (WLC) is the gold-standard technique for detection of bladder cancer. However, the accuracy of WLC in detecting disease is unsatisfactory. The detection reliability of smaller tumors or carcinoma in situ (CIS) may be missed, which leads to that recurrence is remarkably common with up to 30% of patients having tumor identified at the first-check cystoscopy at 3 months and 50% of patients developing a recurrence within the first year <sup>4,5</sup>. Thus, different optical imaging techniques have emerged as an adjunct to WLC to improve visualization of tumors by means of contrast enhancement.

Photodynamic diagnosis (PDD) is performed using blue-violet (380-440nm) light after intravesical instillation of 5-aminolevulinic acid (5-ALA) or hexaminolevulinic acid (HAL). The effect of 5-ALA induced fluorescence on tumor detection in the urinary bladder has been assessed to be an efficient method of mapping the entire mucosa to detect urothelial tumors and flat CIS lesions <sup>6-8</sup>. HAL is the lipophilic hexylester of 5-ALA and has been commercially available since 2006, and has been established as the preferred intravesical agent for detection of NMIBC. However, intravesical inflammation compromised the specificity and priori instillation contributed technical complexity and cost.

Narrow band imaging (NBI) is a new image-processing modality filtering white light down to two narrow band widths of 415 and 540 nm with advantage of avoiding the need for intravesical contrast administration <sup>9</sup>. Hemoglobin absorbs these wavelengths preferentially, which results in dark neovascularized bladder cancer that strongly contrast with light background of normal mucosa to improve detection rates. The effectiveness of NBI for increasing tumor detection has been confirmed in several studies <sup>10-12</sup>. Overall, NBI yield a 9.9% increased detection rate on patient level and a 19.2% increase on lesion level in a recent meta-

analysis, while subgroup analysis showed NBI was associated with 53% reduction in recurrence rate at 3 months and 19% at 12 months compared with WLC<sup>13</sup>. However, NBI may result in increased false-positives, especially for patients with prior intravesical instillations<sup>14</sup>.

Although several studies demonstrated the diagnostic superiority of novel image technique-assisted transurethral resection. It is still uncertain that which technique could better improve diagnosis accuracy of bladder cancer detection. In this study, the specific objective was to perform a systematic review and diagnosis meta-analysis assessing the diagnostic performance of PDD using 5-ALA, PDD using HAL, and NBI against the reference standard of WLC for NMIBC.

## Methods

The diagnostic meta-analysis was conducted based on the Meta-analysis of Observational Studies in Epidemiology statement<sup>15</sup>. When an included primary study did not match the Standards for Reporting of Diagnostic Accuracy statement, we gathered the information by the authors<sup>16</sup>.

### *Literature search*

All studies reporting the diagnostic performance of PDD with 5-ALA, PDD with HAL, or NBI, with WLC as reference standard, were retrieved from multiple databases including PubMed/MEDLINE, Web of Science, the Cochrane Library, Central Register of Controlled Trials and Embase up to 31<sup>st</sup> March 2018. The following MeSH free and combined terms which were adjusted for the different databases terms were used: “photodynamic diagnoses, PDD, hexaminolevulinate, HAL, 5-aminolevulinate acid, 5-ALA, narrow imaging, NBI, white light cystoscopy, bladder cancer, bladder tumor and BCa.” The review was performed according to Preferred Reporting Items for Systematic Reviews (PRISMA)<sup>17</sup> and Standards for Reporting Diagnostic Accuracy Studies (STARD)<sup>18</sup>. The search was restricted to English-language publications. At least two reviewers (CHC and HH) screened all abstracts and full-text articles independently. Disagreement

was resolved by consensus via discussion with an independent arbiter (JH).

### ***Inclusion and exclusion criteria***

Inclusion criteria included the following elements: 1) Population: Patients with suspected NMIBC in the primary setting (i.e. primary diagnosis), or patients with previously confirmed NMIBC undergoing surveillance (i.e. diagnosis of recurrent tumors); 2) Reference standard: All patients must have had WLC as the reference standard, with positive or negative cases being denoted by the presence or absence of NMIBC confirmed by histopathological examination; 3) Diagnostic performance should be compared in intra-patient groups. 4) Diagnostic performance outcomes: Diagnostic Odds Ratios (DOR) and Area Under the Receiver Operating Characteristic Curve (AUROC) in patient or lesion level. When two or more studies reported on a group of patients at the same institution during an overlapping time period, only the article with the latest data set was included, unless different outcomes were reported or different subgroup analyses were performed.

Articles were excluded if the full-text article was not written in English. Abstracts, conference articles, historical overviews, case studies, reviews, and meta-analysis were not considered. Studies that failed to report on sensitivity and/or specificity data as compared with WLC were excluded. For missing or unclear data, we contacted the authors to get more information.

### ***Study Quality***

The Quality Assessment of Diagnostic Studies-2 (QUADAS-2)<sup>19</sup> and the Strength Of Recommendation Taxonomy (SORT) numerical scale were applied on included studies<sup>20</sup>. Both checklist were performed independently by two authors (YZ and CHC); disagreement was resolved by discussion or with an independent arbiter (JH). We arbitrarily defined “low RoB” as at least 3 domains scoring “low” across both categories without any domains scoring “high” across either category; “moderate RoB” as at least 2 domains scoring “low” across both categories and without any domain scoring “high” across either



category; all other scoring patterns were defined as “high” RoB.

### **Data Extraction**

The following data were extracted from the selected studies: 1) study characteristics (first author, study design, number of patients, follow-up); 2) intervention characteristics (index tests, duration of follow-up, schedule and nature of WLC); 3) patient characteristics (age, sex, NMIBC patients, tumor lesions, disease grade and stage, disease setting, duration of follow-up); 4) diagnostic performance measure (sensitivity: SSY; specificity: SPY; negative predictive value: NPV; positive predictive value: PPV; false positive rate: FPR; false negative rate: FNR). Data was extracted from each study at lesion or patient level to assess 5-ALA, HAL and NBI as the index test using WLC as the reference standard, with positive or negative disease as determined by histopathological examination.

The Primary outcomes of SSY, SPY, NPV, PPV, FPR and FNR for individual studies were calculated with the following standard definitions. SSY was defined as the proportion of index test-positive patients or lesions out of all cases of WLC-positive findings. SPY referred to the proportion of index test-negative patients or lesions out of all cases of WLC-negative findings. NPV was defined as the proportion of true negatives (i.e. negative index test and negative WLC) out of all index test-negative cases or lesions; PPV was defined as the proportion of true positives (i.e. positive index test and positive WLC) out of all index test-positive cases or lesions. FNR was defined as the proportion of index test-negative cases or lesions out of all cases of WLC-positive findings (i.e.  $1 - SSY$ ); FPR was defined as the proportion of index test-positive cases or lesions out of all cases of WLC-negative findings (i.e.  $1 - SPY$ ). FP cases or lesions referred to patients who had index test-positive findings whilst WLC found negative findings.

### **Statistical analysis**

Separate meta-analyses were performed for the currently new technology-assisted cystoscopy in NMIBC patients to best summarize the totality of the available evidence. The pooled estimates for DOR and AUROC

with 95% confidence intervals (CIs) of the compared end points were used in our diagnostic meta-analysis. The AUROC is an overall summary measure index of the diagnostic accuracy. A perfect test will have an AUROC close to 1 and a poor test has AUROC close to 0.5<sup>21</sup>. We formulated forest plots of the summary measures of accuracy and examined the heterogeneity of the summary measures of sensitivity and specificity with a random effects model. The publication bias was assessed using Deeks' funnel plot, and statistical significance was determined with Deeks' asymmetry test<sup>22 23</sup>. A two-sided p value of less than 0.05 was considered significant. The diagnostic meta-analysis was performed using Stata 13.0 (StataCorp, College Station, TX, USA). Results were plotted on Summary Receiver Operating Curve (SROC) using RevMan 5.2 software. To explore the effect of heterogeneity on the results, sensitivity analyses were planned based on disease grade (low grade vs high grade), stage (pTa vs pT1), setting (primary vs recurrent tumours), number of participants (studies with n>100 patients only), and on studies with low to moderate RoB.

## Results

### *Search and Study Selection*

The flow diagram summarizing the literature screening and inclusion process is presented in Figure 1. Of the 652 potentially relevant articles identified in the database search, 271 studies were excluded for duplication. We excluded 278 studies when screening titles and abstracts: 32 editorials or letters, 24 reviews or meeting abstracts, 85 non-comparative studies and 137 papers on an obviously different topic. During the screening of 103 full-text articles, 36 studies were excluded for not being relevant to this review and another 41 studies were excluded for not having within-patient comparisons. Finally, 26 studies<sup>12 24-48</sup> were included in the diagnostic meta-analysis.

### *Study Demographics*

The characteristics of the 26 studies included in this meta-analysis are summarized in Table 1. The

11 interventions were 5-ALA-based PDD in 9 studies, HAL-based PDD in 8 studies, and NBI in 9 studies. The  
2  
3  
4 studies were published from 1994 to 2016, and the sample size ranged from 12 to 605 participants, with a  
5  
6 median sample size of 95.5. The mean or median age in the studies was quite similar. Likewise, the  
7  
8 male/female ratio showed no differences. Most enrolled patients in included studies were NMIBC.

### 11 *Lesion level analysis*

14 All studies used non-standardized definitions to calculate their diagnostic outcomes, in which case the  
15  
16 results of included studies were recalculated using standard definitions with the raw data provided  
17  
18 (Supplementary Table 1). The diagnostic meta-analysis results were presented in lesion-level and patient-  
19  
20 level analyses. Based on lesion level, the forest plot of estimates of DOR for NBI, HAL and 5-ALA  
21  
22 compared with WLC were showed in Figure 2, the pooled DOR for NBI, HAL and 5-ALA were 40.09 (95%  
23  
24 CI, 20.08-80.01, Figure 2A), 78.14 (95% CI, 31.42-194.28, Figure 2C) and 18.14 (95% CI, 4.28-76.87,  
25  
26 Figure 2E). The SROC curves for NBI, HAL and 5-ALA were showed in Figure 3A, the AUROC of NBI,  
27  
28 HAL and 5-ALA were 0.88 (95% CI, 0.85-0.91), 0.94 (95% CI, 0.92-0.96) and 0.82 (95% CI, 0.79-0.85).  
29  
30 Importantly, the results of the SSY and SPY for each intervention are shown in Supplementary Figures 1-3.  
31  
32 The pooled estimates for the SSY data for NBI, HAL and 5-ALA were 0.94 (95% CI, 0.82-0.98,  
33  
34 Supplementary Figure 1A), 0.95 (95% CI, 0.91-0.98, Supplementary Figure 2A) and 0.90 (95% CI, 0.71-  
35  
36 0.97, Supplementary Figure 3A), whereas the SPY data for NBI, HAL and 5-ALA were 0.79 (95% CI, 0.73-  
37  
38 0.85, Supplementary Figure 1B), 0.81 (95% CI, 0.74-0.87, Supplementary Figure 2B) and 0.69 (95% CI,  
39  
40 0.57-0.79, Supplementary Figure 3B), presenting superiority compared with WLC. The DOR value and  
41  
42 AUROC of NBI, HAL and 5-ALA presented excellent diagnostic performance.

### 52 *Patient level analysis*

54  
55 As for patient level analysis, the AUROC, SSY and SPY could not be calculated as few studies  
56  
57 included. Figure 2 showed the forest plots of DOR for NBI, HAL and 5-ALA. For NBI, the highest DOR  
58  
59  
60

11 were reached. The DOR for NBI and HAL were 358.71 (95% CI, 44.50-2891.71, Figure 2B) and 59.95  
2  
3  
4 (95% CI, 24.30-147.92, Figure 2D), present better performance compared with WLC. The SROC curves for  
5  
6 NBI, HAL and 5-ALA were showed in Figure 3B. However, the DOR for 5-ALA was 79.52 (95% CI, 0.94-  
7  
8 6759.92, Figure 2F), without statistic difference.

### 11 *Sensitivity Analyses*

14 Sensitivity analyses were performed on studies with low to moderate RoB and at least 100 patients at  
15  
16 lesion level. The diagnostic performance results for studies with low to moderate RoB and at least 100  
17  
18 patients were demonstrated at Supplementary Table 2. The forest plot of estimates of pooled DOR for NBI,  
19  
20 HAL and 5-ALA with low to moderate RoB were showed in Supplementary Figure 4; while forest plot of  
21  
22 estimates of pooled DOR for NBI, HAL and 5-ALA with at least 100 patients were showed in  
23  
24 Supplementary Figure 5. These results showed consistency with those obtained in our overall analysis.  
25  
26  
27  
28

### 29 *RoB of included studies*

31  
32 The comparison-adjusted funnel plots of the diagnostic meta-analysis were not suggestive of any  
33  
34 publication bias, showed in Figure 4. QUADAS-2 tool was applied for RoB assessment of included studies  
35  
36 in our meta-analysis (Supplementary Figure 6). Overall, 69% (18/26) of the studies were judged as having  
37  
38 low or unclear RoB across most domains. All studies clearly reported methodology for the index test and  
39  
40 reference standard, and were not considered a significant source of potential bias. The risk of bias in the  
41  
42 patient selection in 3 studies were deemed high due to the absence of consecutive inclusion of patients; 4  
43  
44 studies were at high RoBs for the flow and timing.  
45  
46  
47  
48  
49

### 50 **Discussion**

51  
52  
53 Our systematic review indicated that pooled diagnostic accuracy of NBI, HAL or 5-ALA showed  
54  
55 excellent diagnostic performance compared with WLC. NBI could potentially be the most promising  
56  
57  
58  
59  
60

11 diagnostic intervention for NMIBC patients with advantages in terms of simplicity, cost and reliability. In  
2  
3  
42 this study, we have summarized the diagnostic performance of new technique-assisted cystoscopy  
5  
63 strategies for NMIBC. Our diagnostic meta-analysis was further undertaken to estimate diagnostic  
7  
8  
94 performance of NBI, HAL and 5-ALA compared with WLC. Since virtually all of the techniques assessed  
10  
11  
12 in this review based on the reference standard of WLC, new technique-assisted cystoscopy showed  
13  
14 diagnostic superiority than conventional WLC. In this context, adoption of these strategies in bladder  
15  
16 cancer diagnosis practice is essential. The present results do strongly suggest that new imaging-based  
17  
18 technologies, in particular NBI, are promising diagnostic intervention for bladder cancer detection in  
19  
20  
21 clinical practice.

23  
24 PDD and NBI both aim at improving the visualization of bladder tumors. Several studies<sup>12 49 50</sup> have  
25  
26 shown the superiority of PDD or NBI over WLC alone in tumor detection. Further meta-analysis enrolling  
27  
28 2807 patients found a 21% increase in tumor detection with PDD over WLC in the pooled estimates for  
29  
30 patients and biopsies<sup>51</sup>. NBI, another optical enhancement technology, improve diagnostic accuracy by  
31  
32 increasing contrast of superficial vasculature between normal mucosa and tumor tissue. Previous studies  
33  
34 reported significant detection improvement in bladder tumors with NBI cystoscopy compared with standard  
35  
36 WLC<sup>12 14</sup>. Our former meta-analysis indicated that NBI provides an additional 17% of patients and an  
37  
38 additional 24% of tumors compared with WLC<sup>52</sup>. However, these studies did not use standardized  
39  
40 diagnostic accuracy definitions. Our diagnostic meta-analysis applied standard diagnostic accuracy  
41  
42 definitions and further pooled estimates demonstrated new technique assisted cystoscopy showed  
43  
44 significant diagnostic superiority than conventional WLC, demonstrating the sub-optimal performance of  
45  
46 WLC in diagnosing NMIBC.

47  
48 Study performed by Burger<sup>53</sup> showed that PDD using HAL significantly reduced recurrence rate at 9–12  
49  
50 months compared with WLC-assisted TUR alone. Also, Lee et al performed a meta-analysis<sup>54</sup> evaluating  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

11 oncologic outcomes for WLC, PDD- and NBI-assisted TUR, which showed both PDD and NBI reduced  
2  
3  
4 recurrence rate compared with WLC. However, therapeutic effectiveness of new technique assisted TUR  
5  
6 such as recurrence and progression could not be demonstrated in this review. Future therapeutic efficacy  
7  
8  
9 analysis was needed to identify promising intervention.

11 The strengths of our study include the stringent methodology used to synthesize the evidence obtained,  
12  
13  
14 such as adhering to PRISMA guidelines, using standardized definitions of diagnostic performance analysis  
15  
16 and applying QUADAS-2 tool for RoB assessment. Moreover, the strict diagnostic meta-analysis and  
17  
18 further sensitivity analysis was applied to synthesize diagnostic accuracy for reliable result. However,  
19  
20 potential study limitations should be acknowledged. Any biases and inaccuracies within individual studies  
21  
22 would be reflected in our analysis. The lack of data on important clinical variables, such as grade and stage  
23  
24 of disease, primary vs recurrent disease and intravesical instillation settings, may introduce clinical  
25  
26 heterogeneity and prevent further sensitivity analyses. However, we have attempted to minimize biases by  
27  
28 applying rigorous selection criteria during the design phase of our study, standardizing data extraction and  
29  
30 performing several sensitivity analyses to evaluate the robustness of our findings.

31  
32 In summary, this meta-analysis provides pooled diagnostic accuracy for NBI, HAL and 5-ALA  
33  
34 techniques for NMIBC patients compared with WLC as a reference standard. The results demonstrate that  
35  
36 the diagnostic accuracy of NBI, HAL and 5-ALA all superiority than WLC at lesion level in diagnostic  
37  
38 meta-analysis. The findings confirm the excellent diagnostic performance of these new imaging-based  
39  
40 technologies in diagnosing NMIBC in comparison with the present standard using WLC, although well-  
41  
42 designed prospective studies with long-term follow-up may shed more light on their impact on diagnostic  
43  
44 and prognostic outcomes.

45  
46  
47  
48 **Abbreviations** CI: Confidence intervals; CIS: carcinoma in situ; DOR: Diagnostic odds ratios; DTA:  
49  
50 Diagnostic test accuracy; FNR: False negative rate; FPR: False positive rate; IQR: Interquartile range; HAL:

hexylaminolevulinate; NBI: and narrow band imaging; NMIBC: Non-muscle-invasive bladder cancer; NPV: Negative predictive value; PDD: Photodynamic diagnosis; PPV: Positive predictive value; SPY: Specificity; SSY: Sensitivity; SROC: Summary receiver operating curve; AUROC: Area under the receiver operating characteristic curve; TURBT: Transurethral resection of bladder tumors; WLC: White light cystoscopy; 5-ALA: 5-aminolaevulinic acid.

**Acknowledgements** We would like to thank Prof. J.X. Zhang, Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, China, for statistical advice and research comments.

**Contributors** CHC conceptualized and designed the study, drafted the initial and final manuscript, provided funding support. HH contributed to data collection and extraction, data analysis and interpretation, drafted initial and final manuscript. YZ contributed to article screening, data collection and extraction, assessment of risk of bias and drafting manuscript: HL contributed to article screening, data collection and extraction and assessment of risk of bias. RJ Sylvester led and supervised statistical analysis, provided administrative support. TXL and JH contributed to study conceptualization and design, supervised study implementation, and critically reviewed the manuscript.

**Funding** This study was funded by the National Natural Science Foundation of China (Grant No. 81572514,81472384, 81472381, 81402106, 81772719, 81772728, 91740119, 91529301); Guangdong Medical Research Fund (A2018330); Science and Technology Program of Guangzhou (Grant No. 201604020156, 201604020177, 201707010116, 201803010098); National Natural Science Foundation of Guangdong (Grant No. 2018A030313564, 2018B030311009, 2018A030310250,2016A030313321, 2015A030311011, 2015A030310122). Yixian Youth project of Sun Yat-sen Memorial Hospital



1 (YXQH201812).

2  
3  
4  
5  
6 **Competing interests** None declared.

7  
8  
9  
10  
11 **Patient consent** Not required.

12  
13  
14  
15  
16  
17 **Provenance and peer review** Not commissioned; externally peer reviewed.

18  
19  
20  
21  
22 **Data sharing statement** There are no additional data available.

## 23 24 25 26 **References**

- 27 1. Antoni S, Ferlay J, Soerjomataram I, et al. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. *European urology* 2016 doi: 10.1016/j.eururo.2016.06.010
- 28 2. Babjuk M, Bohle A, Burger M, et al. Guidelines on non-muscle-invasive bladder cancer (Ta,T1 and CIS). European Association of  
29 Urology Web site. <http://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/>.
- 30 3. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the  
31 2011 update. *European urology* 2011;59(6):997-1008. doi: 10.1016/j.eururo.2011.03.017 [published Online First:  
32 2011/04/05]
- 33 4. Schwaibold HE, Sivalingam S, May F, et al. The value of a second transurethral resection for T1 bladder cancer. *BJU international*  
34 2006;97(6):1199-201. doi: 10.1111/j.1464-410X.2006.06144.x
- 35 5. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage  
36 Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. *European*  
37 *urology* 2006;49(3):466-5; discussion 75-7. doi: 10.1016/j.eururo.2005.12.031
- 38 6. Grimbergen MCM, van Swol CFP, Jonges TGN, et al. Reduced Specificity of 5-ALA Induced Fluorescence in Photodynamic  
39 Diagnosis of Transitional Cell Carcinoma after Previous Intravesical Therapy. *European urology* 2003;44(1):51-56. doi:  
40 10.1016/s0302-2838(03)00210-0
- 41 7. Daniltchenko DI, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral  
42 resection of superficial bladder cancer: 5-year results of a prospective randomized study. *The Journal of urology*  
43 2005;174(6):2129-33, discussion 33. doi: 10.1097/01.ju.0000181814.73466.14
- 44 8. Kriegmair M, Baumgartner R, Knuchel R, et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin  
45 fluorescence. *The Journal of urology* 1996;155(1):105-9; discussion 09-10. [published Online First: 1996/01/01]
- 46 9. Bryan RT, Shah ZH, Collins SI, et al. Narrow-band imaging flexible cystoscopy: a new user's experience. *Journal of endourology*  
47 2010;24(8):1339-43. doi: 10.1089/end.2009.0598 [published Online First: 2010/07/16]
- 48 10. Naito S, Algaba F, Babjuk M, et al. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised  
49 Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White  
50 Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results.



- 1 *European urology* 2016 doi: 10.1016/j.eururo.2016.03.053
- 2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50
11. Naselli A, Introini C, Timossi L, et al. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. *European urology* 2012;61(5):908-13. doi: 10.1016/j.eururo.2012.01.018
12. Ye Z, Hu J, Song X, et al. A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study. *Scientific reports* 2015;5:10905. doi: 10.1038/srep10905
13. Xiong Y, Li J, Ma S, et al. A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. *PLoS one* 2017;12(2):e0170819. doi: 10.1371/journal.pone.0170819 [published Online First: 2017/02/14]
14. Geavlete B, Multescu R, Georgescu D, et al. Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors--results of a prospective, randomized comparison to the standard approach. *Urology* 2012;79(4):846-51. doi: 10.1016/j.urology.2011.08.081
15. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *Jama* 2000;283(15):2008-12.
16. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *BMJ* 2003;326(7379):41-4.
17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010;8(5):336-41. doi: 10.1016/j.ijsu.2010.02.007 [published Online First: 2010/02/23]
18. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. *BMJ* 2015;351:h5527. doi: 10.1136/bmj.h5527 [published Online First: 2015/10/30]
19. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Annals of internal medicine* 2011;155(8):529-36. doi: 10.7326/0003-4819-155-8-201110180-00009 [published Online First: 2011/10/19]
20. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. *Am Fam Physician* 2004;69(3):548-56.
21. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* 1982;143(1):29-36. doi: 10.1148/radiology.143.1.7063747 [published Online First: 1982/04/01]
22. Song F, Khan KS, Dinnes J, et al. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. *Int J Epidemiol* 2002;31(1):88-95. [published Online First: 2002/03/27]
23. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. *J Clin Epidemiol* 2005;58(9):882-93. doi: 10.1016/j.jclinepi.2005.01.016 [published Online First: 2005/08/09]
24. Zhu YP, Shen YJ, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of clinically unconfirmed positive urine cytology. *Urologia internationalis* 2012;88(1):84-7. doi: 10.1159/000333119
25. Zaak D, Kriegmair M, Stepp H, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. *Urology* 2001;57(4):690-4. [published Online First: 2001/04/18]
26. Tatsugami K, Kuroiwa K, Kamoto T, et al. Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. *Journal of endourology / Endourological Society* 2010;24(11):1807-11. doi: 10.1089/end.2010.0055 [published Online First: 2010/08/17]
27. Song PH, Cho S, Ko YH. Decision Based on Narrow Band Imaging Cystoscopy without a Referential Normal Standard Rather Increases Unnecessary Biopsy in Detection of Recurrent Bladder Urothelial Carcinoma Early after Intravesical Instillation. *Cancer Res Treat* 2016;48(1):273-80. doi: 10.4143/crt.2014.190
28. Shen YJ, Zhu YP, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a "second look" matters? *International urology and nephrology* 2012;44(2):451-7. doi: 10.1007/s11255-011-0036-5
29. Shadpour P, Emami M, Haghdani S. A Comparison of the Progression and Recurrence Risk Index in Non-Muscle-Invasive Bladder Tumors Detected by Narrow-Band Imaging Versus White Light Cystoscopy, Based on the EORTC Scoring System.

- 1 *Nephrourol Mon* 2016;8(1):e33240. doi: 10.5812/numonthly.33240
- 2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50
30. Schmidbauer J, Remzi M, Klatte T, et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. *European urology* 2009;56(6):914-9. doi: 10.1016/j.eururo.2009.07.042
31. Riedl CR, Plas E, Pfluger H. Fluorescence detection of bladder tumors with 5-amino-levulinic acid. *Journal of endourology / Endourological Society* 1999;13(10):755-9. doi: 10.1089/end.1999.13.755 [published Online First: 2000/01/26]
32. Ray ER, Chatterton K, Khan MS, et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. *BJU international* 2010;105(6):789-94. doi: 10.1111/j.1464-410X.2009.08839.x
33. Palou J, Hernandez C, Solsona E, et al. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study. *BJU international* 2015;116(1):37-43. doi: 10.1111/bju.13020
34. Lapini A, Minervini A, Masala A, et al. A comparison of hexaminolevulinate (Hexvix((R))) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study. *Surg Endosc* 2012;26(12):3634-41. doi: 10.1007/s00464-012-2387-0
35. Kobatake K, Mita K, Ohara S, et al. Advantage of transurethral resection with narrow band imaging for non-muscle invasive bladder cancer. *Oncol Lett* 2015;10(2):1097-102. doi: 10.3892/ol.2015.3280
36. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. *The Journal of urology* 2003;170(1):226-9. doi: 10.1097/01.ju.0000060782.52358.04
37. Jeon SS, Kang I, Hong JH, et al. Diagnostic efficacy of fluorescence cystoscopy for detection of urothelial neoplasms. *Journal of endourology / Endourological Society* 2001;15(7):753-9. doi: 10.1089/08927790152596370 [published Online First: 2001/11/08]
38. Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. *BJU international* 2008;102(9):1111-4. doi: 10.1111/j.1464-410X.2008.07846.x
39. Grimbergen MC, van Swol CF, Jonges TG, et al. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. *European urology* 2003;44(1):51-6. [published Online First: 2003/06/20]
40. Geavlete B, Multescu R, Georgescu D, et al. Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors. *Journal of endourology / Endourological Society* 2009;23(6):977-81. doi: 10.1089/end.2008.0574 [published Online First: 2009/05/29]
41. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. *The Journal of urology* 2007;178(1):68-73; discussion 73. doi: 10.1016/j.juro.2007.03.028
42. Filbeck T, Roessler W, Knuechel R, et al. Clinical results of the transurethral resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. *Journal of endourology / Endourological Society* 1999;13(2):117-21. doi: 10.1089/end.1999.13.117 [published Online First: 1999/04/23]
43. Filbeck T, Pichlmeier U, Knuechel R, et al. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? *Urology* 2002;60(6):1025-8. [published Online First: 2002/12/12]
44. Ehsan A, Sommer F, Haupt G, et al. Significance of fluorescence cystoscopy for diagnosis of superficial bladder cancer after intravesical instillation of delta aminolevulinic acid. *Urologia internationalis* 2001;67(4):298-304. [published Online First: 2001/12/13]
45. De Dominicis C, Liberti M, Perugia G, et al. Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder cancer: improvement in diagnostic sensitivity. *Urology* 2001;57(6):1059-62. [published Online First: 2001/05/30]
46. D'Hallewin MA, Vanherzeele H, Baert L. Fluorescence detection of flat transitional cell carcinoma after intravesical instillation of aminolevulinic acid. *American journal of clinical oncology* 1998;21(3):223-5. [published Online First: 1998/06/17]
47. Cauberg EC, Kloen S, Visser M, et al. Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder

- 1 cancer. *Urology* 2010;76(3):658-63. doi: 10.1016/j.urology.2009.11.075
- 2 48. Burgues JP, Conde G, Oliva J, et al. [Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer:
- 3 experience of the BLUE group]. *Actas urologicas espanolas* 2011;35(8):439-45. doi: 10.1016/j.acuro.2011.03.003
- 4 [published Online First: 2011/05/31]
- 5 49. Babjuk M, Soukup V, Petrik R, et al. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection
- 6 reduces the risk of recurrence in stage Ta/T1 bladder cancer. *BJU international* 2005;96(6):798-802. doi: 10.1111/j.1464-
- 7 410X.2004.05715.x [published Online First: 2005/09/13]
- 8 50. Gkritisios P, Hatzimouratidis K, Kazantzidis S, et al. Hexaminolevulinate-guided transurethral resection of non-muscle-invasive
- 9 bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial.
- 10 *International urology and nephrology* 2014;46(5):927-33. doi: 10.1007/s11255-013-0603-z
- 11 51. Mowatt G, N'Dow J, Vale L, et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic
- 12 review and meta-analysis. *International journal of technology assessment in health care* 2011;27(1):3-10. doi:
- 13 10.1017/S0266462310001364
- 14 52. Li K, Lin T, Fan X, et al. Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-
- 15 analysis. *International journal of urology : official journal of the Japanese Urological Association* 2013;20(6):602-9. doi:
- 16 10.1111/j.1442-2042.2012.03211.x
- 17 53. Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with
- 18 hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. *Eur Urol* 2013;64(5):846-
- 19 54. doi: 10.1016/j.eururo.2013.03.059
- 20 54. Lee JY, Cho KS, Kang DH, et al. A network meta-analysis of therapeutic outcomes after new image technology-assisted
- 21 transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs
- 22 hexylaminolevulinate fluorescence vs narrow band imaging. *BMC cancer* 2015;15:566. doi: 10.1186/s12885-015-1571-8
- 23 24 55. Burgues JP, Conde G, Oliva J, et al. [Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer:
- 25 experience of the BLUE group]. *Actas urologicas espanolas* 2011;35(8):439-45. doi: 10.1016/j.acuro.2011.03.003
- 26 [published Online First: 2011/05/31]
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

11 **Figure legend**

2  
3  
42 **Figure 1.** The PRISMA flow chart of included studies in DTA analysis.

5  
63 **Figure 2.** The Forest Plot of estimates of DOR for NBI (A), HAL (C), 5-ALA (E) in lesion level and  
7  
8 estimates of DOR for NBI (B), HAL (D), 5-ALA (F) in patient level.

94  
10  
11 **Figure 3.** The SROC curve for NBI, HAL and 5-ALA diagnosing NMIBC in lesion level (A) and patient  
12  
13 level (B).


14  
15  
16 **Figure 4.** Deeks' funnel plot with asymmetry test for NBI (A), HAL (B) and 5-ALA (C) in lesion level.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1 Summary of the characteristics of the included studies**

Study	Institution No.	patients	Index test	period	Age, mean (range)	Male (%)	NMIBC (%)	Tumor lesions (n)
Shadpour et al. <sup>29</sup>	Unicentre	50	NBI	2012-2013	63.86 ± 10.05	34(68.0)	100	95
Song et al. <sup>27</sup>	Unicentre	63	NBI	2012-2013	66(56-76)	39(61.9)	94.1	21
Kobotake et al. <sup>35</sup>	Unicentre	135	NBI	2010-2014	75	110(81.5)	100	120
Ye et al. <sup>12</sup>	Multicentre	384	NBI	NR	61(21-79)	267(69.5)	100	167
Shen et al. <sup>28</sup>	Unicentre	78	NBI	2009-2010	68 (33–75)	62(79.5)	100	211
Zhu et al. <sup>24</sup>	Unicentre	12	NBI	2009-2010	57(28-73)	9(75.0)	100	9
Tatsugami et al. <sup>26</sup>	Unicentre	104	NBI	2007-2009	70.6 (38-90)	88(84.6)	NR	110
Cauberg et al. <sup>47</sup>	Multicentre	95	NBI	2007-2009	70.6 (38.1-90.2)	70(73.7)	NR	226
Herr et al. <sup>38</sup>	Unicentre	427	NBI	2007	65 (26-90)	316(74.0)	100	NR
Palou et al. <sup>33</sup>	Multicentre	283	HAL	2008-2009	67.5(42-95)	242(85.5)	94.1	621
Lapini et al. <sup>34</sup>	Multicentre	96	HAL	2010-2011	NR	80(83.3)	NR	108
Burgues et al. <sup>55</sup>	Multicentre	305	HAL	2006-2009	66.9(39-93)	270(88.5)	100	600
Ray et al. <sup>32</sup>	Unicentre	27	HAL	2005-2006	70(49-82)	21(77.8)	100	NR
Schmidbauer et al. <sup>30</sup>	Unicentre	66	HAL	NR	63(38-84)	49(74.2)	93.1	NR
Geavlete et al. <sup>40</sup>	Unicentre	128	HAL	2007-2008	65(36-81)	NR	92.2	NR
Fradet et al. <sup>41</sup>	Multicentre	298	HAL	NR	67±11	223(74.8)	100	113
Jichlinski et al. <sup>36</sup>	Multicentre	52	HAL	2000-2001	72±12	38(73.1)	100	143
Grimbergen et al. <sup>6</sup>	Unicentre	160	5-ALA	1998-2002	67(30-91)	NR	90.0%	390
Filbeck et al. <sup>43</sup>	Unicentre	279	5-ALA	1997-2000	34-89	NR	90.3%	336
Dominicis et al.	Unicentre	49	5-ALA	NR	60(31-77)	42(85.7)	100	52

1	Al.2001 <sup>45</sup>								
2	Ehsan et	Unicentre	30	5-ALA	NR	55-89	19(63.3)	NR	NR
3	Al.2001 <sup>44</sup>								
4	Jeon at	Unicentre	62	5-ALA	1997-1999	61.9(32-80)	57(91.1)	NR	148
5	Al.2001 <sup>37</sup>								
6	Zaak et	Unicentre	605	5-ALA	NR	65.6(16-99)	472(78.0)	NR	552
7	Al.2001 <sup>25</sup>								
8	Filbeck et	Unicentre	123	5-ALA	1997	64.5(28-86)	NR	91.9	124
9	Al.1999 <sup>42</sup>								
10	Riedl et	Unicentre	52	5-ALA	NR	44-79	NR	100	123
11	Al.1999 <sup>31</sup>								
12	D'hallewin et	Unicentre	16	5-ALA	NR	NR	NR	100	50
13	Al.1998 <sup>46</sup>								

17 WLC: white light cystoscopy; NT: new technology; 5-ALA: 5-aminolaevulinic acid; HAL: hexylaminolevulinate; NBI: narrow  
 18 band imaging; NR: not reported.  
 19



26  
27 Figure 1. The PRISMA flow chart of included studies in DTA analysis.

28 177x108mm (300 x 300 DPI)




Figure 2. The Forest Plot of estimates of DOR for NBI (A), HAL (C), 5-ALA (E) in lesion level and estimates of DOR for NBI (B), HAL (D), 5-ALA (F) in patient level.

177x180mm (300 x 300 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3. The SROC curve for NBI, HAL and 5-ALA diagnosing NMIBC in lesion level (A) and patient level (B).

177x94mm (300 x 300 DPI)






Figure 4. Deeks' funnel plot with asymmetry test for NBI (A), HAL (B) and 5-ALA (C) in lesion level.

177x147mm (300 x 300 DPI)


## Supplementary Information



**Supplementary Figure 1.** The Forest Plot of study specific and pooled sensitivity (A) and specificity (B) for NBI in lesion level.




**Supplementary Figure 2.** The Forest Plot of study specific and pooled sensitivity (A) and specificity (B) for HAL in lesion level.




**Supplementary Figure 3.** The Forest Plot of study specific and pooled sensitivity (A) and specificity (B) for 5-ALA in lesion level.


A



B




C




Supplementary Figure 4. The Forest Plot of estimates of DOR for NBI (A), HAL (B) and 5-ALA (C) with low to moderate RoB in lesion level.


A



B



C



**Supplementary Figure 5.** The Forest Plot of estimates of DOR for NBI (A), HAL (B) and 5-ALA (C) with at least 100 patients in lesion level.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



**Supplementary Figure 6.** Quality assessment of included studies. The distribution plot for risk of bias using QUADAS-2 tool. Studies are deemed to be at high, low or unclear risk of bias for each domain.

For peer review only



**Supplementary Table 1. Diagnostic performance results of individual studies for Meta-analysis**

Study ID	Patient-level analysis							Lesion-level analysis						
	Patient No.	SSY	SPY	FP R	FN R	PP V	NP V	Lesion No.	SSY	SPY	FPR	FN R	PP V	NP V
<b>NBI vs WLC</b>														
<b>Shadpour et al.2016<sup>1</sup></b>	50	NR	NR	NR	NR	NR	NR	175	69/80	70/85	15/85	11/80	69/84	74/75
<b>Song et al.2016<sup>2</sup></b>	63	16/16	46/47	1/47	0/1	16/16	23/23	66	19/19	45/47	2/47	0/1	19/21	7/7
<b>Kobota et al.2015<sup>3</sup></b>	135	NR	NR	NR	NR	NR	NR	379	78/84	227/263	36/263	6/84	78/114	203/203
<b>Ye et al.2015<sup>4</sup></b>	103	56/56	16/45	29/46	0/5	56/86	8/8	300	124/126	92/133	41/133	2/126	124/165	83/85
<b>Shen et al.2012<sup>5</sup></b>	78	47/47	9/22	13/22	0/4	47/47	7/7	309	160/160	98/134	36/134	0/134	160/196	72/2
<b>Zhu et al.2012<sup>6</sup></b>	12	NR	NR	NR	NR	NR	NR	31	4/6	19/22	3/22	2/6	4/7	20/20
<b>Tatsugami et al.2010<sup>7</sup></b>	104	NR	NR	NR	NR	NR	NR	313	55/63	156/203	47/203	8/63	55/102	144/144
<b>Cauberg et al.2009<sup>8</sup></b>	95	NR	NR	NR	NR	NR	NR	389	167/179	116/163	47/163	12/179	167/214	47/51
<b>Herr et al.2008<sup>9</sup></b>	427	90/90	311/324	13/24	0/90	90/103	265/265	NR	NR	NR	NR	NR	NR	NR
<b>HAL vs WLC</b>														
<b>Palou et al.2014<sup>10</sup></b>	283	NR	NR	NR	NR	NR	NR	1492	379/416	820/948	128/948	37/416	379/507	699/702
<b>Lapini et al.2012<sup>11</sup></b>	96	NR	NR	NR	NR	NR	NR	234	82/83	101/126	25/126	1/83	82/107	80/81
<b>Burgues et al.2011<sup>12</sup></b>	305	NR	NR	NR	NR	NR	NR	1659	404/441	900/1059	159/1059	7/41	404/563	863/863

1	<b>Ray et</b>	27	NR	NR	NR	NR	NR	NR	120	21/2	84/9	10/9	0/2	21/3	35/3
2	<b>al.2010<sup>1</sup></b>									1	4	4	1	1	5
3	<b>3</b>														
4	<b>Schmid</b>	66	52/5	2/8	6/8	0/5	52/5	3/3	364	109/	151/	50/2	4/1	109/	158/
5	<b>bauer</b>		2			2	8			113	201	01	13	159	158
6	<b>et</b>														
7	<b>al.2009<sup>1</sup></b>														
8	<b>4</b>														
9	<b>Geavlet</b>	128	NR	NR	NR	NR	NR	NR	243	87/9	56/1	47/1	6/9	87/1	76/8
10	<b>e et</b>									3	03	03	3	34	2
11	<b>al.2008<sup>1</sup></b>														
12	<b>5</b>														
13	<b>Fradet</b>	196	40/4	128/	10/1	8/4	40/5	106/	206	77/8	101/	11/1	6/8	77/8	63/7
14	<b>et</b>		8	138	38	8	0	113		3	112	12	3	8	1
15	<b>al.2006<sup>1</sup></b>														
16	<b>6</b>														
17	<b>Jichlins</b>	52	33/3	7/17	10/1	0/3	33/4	3/3	143	205/	269/	74/3	49/	205/	306/
18	<b>ki et</b>		3		7	3	3			254	343	43	254	279	314
19	<b>al.2003<sup>1</sup></b>														
20	<b>7</b>														
21	<b>5-ALA</b>														
22	<b>vs</b>														
23	<b>WLC</b>														
24	<b>Grimbe</b>	160	NR	NR	NR	NR	NR	NR	889	232/	409/	118/	12/	232/	248/
25	<b>rgen et</b>									244	527	527	244	350	257
26	<b>al.2003<sup>1</sup></b>														
27	<b>8</b>														
28	<b>Filbeck</b>	279	168/	93/1	9/10	0/1	168/	81/8	NR	NR	NR	NR	NR	NR	NR
29	<b>et</b>		168	02	2	68	177	1							
30	<b>al.2002<sup>1</sup></b>														
31	<b>9</b>														
32	<b>Domini</b>	49	NR	NR	NR	NR	NR	NR	179	2/9	84/1	43/1	7/9	2/45	80/8
33	<b>cis et</b>										27	27		0	
34	<b>al.2001<sup>2</sup></b>														
35	<b>0</b>														
36	<b>Ehsan</b>	30	NR	NR	NR	NR	NR	NR	151	39/4	71/9	20/9	1/4	39/5	59/5
37	<b>et</b>									0	1	1	0	9	9
38	<b>al.2001<sup>2</sup></b>														
39	<b>1</b>														
40	<b>Jeon at</b>	62	NR	NR	NR	NR	NR	NR	257	71/7	69/1	57/1	3/7	71/1	54/5
41	<b>al.2001<sup>2</sup></b>									4	26	26	4	28	4
42	<b>2</b>														
43	<b>Zaak et</b>	605	288/	271/	189/	75/	288/	55/1	NR	NR	NR	NR	NR	NR	NR
44	<b>al.2001<sup>2</sup></b>		363	460	460	363	477	08							
45	<b>3</b>														
46	<b>Filbeck</b>	123	NR	NR	NR	NR	NR	NR	341	75/8	185/	38/2	5/8	75/1	78/7
47	<b>et</b>									0	223	23	0	13	8

1 **al.1999<sup>2</sup>**

2 4

3 **Riedl et** 52 26/2 10/1 8/18 0/2 26/3 6/6 NR NR NR NR NR NR NR

4 **al.1999<sup>2</sup>** 6 8 6 4

5 5

6 **D'Halle** 16 NR NR NR NR NR NR 113 11/1 27/6 36/6 3/1 11/4 34/3

7 **win et** 4 3 3 4 7 4

8 **al.1998<sup>2</sup>**

9 6

10

11

---

12 NMIBC: non-muscle-invasive bladder cancer; WLC: white light cystoscopy; 5-ALA: 5-aminolaevulinic  
 13 acid; HAL: hexylaminolevulinate; NBI: narrow band imaging; NT: new technology; SSY: sensitivity; SPY:  
 14 specificity; FPR: false positive rate; FNR: false negative rate; PPV: positive predictive value; NPV: negative  
 15 predictive value; NR: not reported.

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

**Supplementary Table2. Diagnostic performance results for sensitivity analysis of studies with low to moderate RoB and at least 100 patients at lesion level.**

	Low to moderate RoB			At least 100 patients		
	Median	Lower Quartile	Upper Quartile	Median	Lower Quartile	Upper Quartile
<b>NBI vs WLC (n=6)</b>				<b>NBI vs WLC (n=3)</b>		
Sensitivity	95.85	88.80	99.60	92.86	90.08	95.63
Specificity	74.99	71.66	80.98	76.85	73.01	81.58
Positive predictive value	79.84	75.87	82.02	68.42	61.17	71.79
Negative predictive value	99.33	97.90	100	100	98.82	100
False positive rate	25.01	19.02	28.34	23.15	18.42	26.99
False negative rate	4.15	0.40	11.20	7.14	4.37	9.92
<b>HAL vs WLC (n=6)</b>				<b>HAL vs WLC (n=4)</b>		
Sensitivity	95.00	92.97	98.21	92.19	91.48	92.97
Specificity	83.33	76.38	88.65	85.74	77.33	87.42
Positive predictive value	71.65	67.94	76.16	73.26	70.05	77.94
Negative predictive value	99.17	94.20	99.89	96.13	91.70	99.68
False positive rate	16.67	11.35	23.62	14.26	12.58	22.67
False negative rate	5.00	1.79	7.03	6.84	5.24	7.65
<b>5-ALA vs WLC (n=4)</b>				<b>5-ALA vs WLC (n=2)</b>		
Sensitivity	95.51	94.75	96.33	94.42	-	-
Specificity	77.82	71.90	79.26	80.28	-	-
Positive predictive value	66.19	63.44	66.31	66.33	-	-
Negative predictive value	100	99.12	100	98.25	-	-
False positive rate	22.18	20.74	28.10	19.72	-	-
False negative rate	4.49	3.67	5.25	5.58	-	-

NMIBC: non-muscle-invasive bladder cancer; WLC: white light cystoscopy; 5-ALA: 5-aminolaevulinic acid; HAL: hexylaminolevulinate; NBI: narrow band imaging; NR: not reported.

## References

1. Shadpour P, Emami M, Haghani S. A Comparison of the Progression and Recurrence Risk Index in Non-Muscle-Invasive Bladder Tumors Detected by Narrow-Band Imaging Versus White Light Cystoscopy, Based on the EORTC Scoring System. *Nephrourol Mon* 2016; 8(1):e33240.
2. Song PH, Cho S, Ko YH. Decision Based on Narrow Band Imaging Cystoscopy without a Referential Normal Standard Rather Increases Unnecessary Biopsy in Detection of Recurrent Bladder Urothelial Carcinoma Early after Intravesical Instillation. *Cancer Res Treat* 2016; 48(1):273-80.
3. Kobatake K, Mita K, Ohara S, et al. Advantage of transurethral resection with narrow band imaging for non-muscle invasive bladder cancer. *Oncol Lett* 2015; 10(2):1097-1102.
4. Ye Z, Hu J, Song X, et al. A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study. *Sci Rep* 2015; 5:10905.
5. Shen YJ, Zhu YP, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a "second look" matters? *Int Urol Nephrol* 2012; 44(2):451-7.
6. Zhu YP, Shen YJ, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of clinically unconfirmed positive urine cytology. *Urol Int* 2012; 88(1):84-7.
7. Tatsugami K, Kuroiwa K, Kamoto T, et al. Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. *J Endourol* 2010; 24(11):1807-11.
8. Cauberg EC, Kloen S, Visser M, et al. Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. *Urology* 2010; 76(3):658-63.
9. Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. *BJU Int* 2008; 102(9):1111-4.
10. Palou J, Hernandez C, Solsona E, et al. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study. *BJU Int* 2015; 116(1):37-43.
11. Lapini A, Minervini A, Masala A, et al. A comparison of hexaminolevulinate (Hexvix((R))) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study. *Surg Endosc* 2012; 26(12):3634-41.
12. Burgues JP, Conde G, Oliva J, et al. [Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group]. *Actas Urol Esp* 2011; 35(8):439-45.
13. Ray ER, Chatterton K, Khan MS, et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. *BJU Int* 2010; 105(6):789-94.
14. Schmidbauer J, Remzi M, Klatter T, et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. *Eur Urol* 2009; 56(6):914-9.
15. Geavlete B, Multescu R, Georgescu D, et al. Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors. *J Endourol* 2009; 23(6):977-81.
16. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. *J Urol* 2007; 178(1):68-73; discussion 73.
17. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. *J Urol* 2003; 170(1):226-9.
18. Grimbergen MCM, van Swol CFP, Jonges TGN, et al. Reduced Specificity of 5-ALA Induced Fluorescence in Photodynamic Diagnosis of Transitional Cell Carcinoma after Previous Intravesical Therapy. *European Urology* 2003; 44(1):51-56.
19. Filbeck T, Pichlmeier U, Knuechel R, et al. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? *Urology* 2002; 60(6):1025-8.

- 1 20. De Dominicis C, Liberti M, Perugia G, et al. Role of 5-aminolevulinic acid in the diagnosis and  
2 treatment of superficial bladder cancer: improvement in diagnostic sensitivity. *Urology* 2001;  
3 57(6):1059-62.
- 4 21. Ehsan A, Sommer F, Haupt G, et al. Significance of fluorescence cystoscopy for diagnosis of superficial  
5 bladder cancer after intravesical instillation of delta aminolevulinic acid. *Urol Int* 2001; 67(4):298-  
6 304.
- 7 22. Jeon SS, Kang I, Hong JH, et al. Diagnostic efficacy of fluorescence cystoscopy for detection of  
8 urothelial neoplasms. *J Endourol* 2001; 15(7):753-9.
- 9 23. Zaak D, Kriegmair M, Stepp H, et al. Endoscopic detection of transitional cell carcinoma with 5-  
10 aminolevulinic acid: results of 1012 fluorescence endoscopies. *Urology* 2001; 57(4):690-4.
- 11 24. Filbeck T, Roessler W, Knuechel R, et al. Clinical results of the transurethral resection and evaluation  
12 of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of  
13 5-aminolevulinic acid. *J Endourol* 1999; 13(2):117-21.
- 14 25. Riedl CR, Plas E, Pfluger H. Fluorescence detection of bladder tumors with 5-amino-levulinic acid. *J*  
15 *Endourol* 1999; 13(10):755-9.
- 16 26. D'Hallewin MA, Vanherzeele H, Baert L. Fluorescence detection of flat transitional cell carcinoma  
17 after intravesical instillation of aminolevulinic acid. *Am J Clin Oncol* 1998; 21(3):223-5.
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	Title page
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5-6
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	None
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7-8
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	7
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	Figure 1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8-9
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> for each meta-analysis).	9-10



# PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	10
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	11
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	11
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Supplementary Figure 6
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Supplementary Table 1
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	11-12
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	13
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	12
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14-15
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	15-16
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	17-18

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097.





# PRISMA 2009 Checklist

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only

# BMJ Open

## Diagnostic Performance of Image Technique Based Transurethral Resection for Non-muscle Invasive Bladder Cancer: Systematic Review and Diagnostic Meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028173.R1
Article Type:	Original research
Date Submitted by the Author:	06-Aug-2019
Complete List of Authors:	Chen, Changhao; Sun Yat-Sen Memorial Hospital, Department of Urology Huang, Hao; Sun Yat-Sen Memorial Hospital, Department of Urology Zhao, Yue; the First Affiliated Hospital of Sun Yat-Sen University, Department of Gastroenterology Liu, Hao; Chengdu Fifth People's Hospital, Department of Urology Sylvester, Richard; EAU Guidelines Office, Brussels Lin, Tianxin; Sun Yat-Sen Memorial Hospital, Department of Urology Huang, Jian; Sun Yat-Sen Memorial Hospital, Department of Urology
<b>Primary Subject Heading</b>:	Urology
Secondary Subject Heading:	Diagnostics
Keywords:	bladder cancer, diagnostic performance, Narrow band imaging, photodynamic diagnosis, white light-guided cystoscopy

SCHOLARONE™  
Manuscripts

11 **Diagnostic Performance of Image Technique Based Transurethral Resection for Non-muscle Invasive**  
12  
13  
14 **Bladder Cancer: Systematic Review and Diagnostic Meta-analysis**

15 Changhao Chen<sup>1,2#</sup>; Hao Huang<sup>1,2#</sup>; Yue Zhao<sup>3#</sup>; Hao Liu<sup>4</sup>; Richard J. Sylvester<sup>5</sup>; Tianxin Lin<sup>1,2\*</sup>; Jian  
16  
17 Huang<sup>1,2\*</sup>

18 <sup>1</sup>Department of Urology, <sup>2</sup>Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene  
19 Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong, P. R. China

20 <sup>3</sup> Department of Interventional Oncology, Sun Yat-Sen University First Affiliated Hospital, Guangzhou,  
21  
22 China;

23 <sup>4</sup>Department of Urology, Chengdu Fifth People's Hospital, Chengdu, P. R. China

24 <sup>5</sup>European Association of Urology Guidelines Office, Arnhem, Netherlands

25  
26  
27 #These authors contributed equally to this study.

28  
29  
30 \*Corresponding authors, to whom requests for reprints should be addressed.

31  
32  
33 Jian Huang MD, PhD

34  
35  
36 Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yan-Jiang Xi Road,  
37  
38 Guangzhou, 510120, China

39  
40  
41 Tel. +86 20 81332603; Fax: +86 20 81332853.

42  
43  
44 E-mail address: [cch1988@163.com](mailto:cch1988@163.com)

45  
46  
47 Tianxin Lin MD, PhD

48  
49  
50 Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yan-Jiang Xi Road,  
51  
52 Guangzhou, 510120, China

53  
54  
55 Tel. +86 20 81332603; Fax: +86 20 81332853.

56  
57  
58 E-mail address: [tianxinl@sina.com](mailto:tianxinl@sina.com)

## Abstract

**Objective** To explore diagnostic performance of image technique based transurethral resection for bladder cancer, with white light-guided cystoscopy (WLC) as reference standard.

**Design** Systematic review and meta-analysis.

**Data sources** PubMed/MEDLINE, Web of Science, the Cochrane Library, Central Register of Controlled Trials and Embase from inception through 31<sup>st</sup> March 2018.

**Methods** We included studies reporting diagnostic performance of PDD with 5-ALA, PDD with HAL, or NBI, with WLC as reference standard in patient or lesion level. Study risk of bias was assessed using the Quality Assessment of Diagnostic Studies-2 (QUADAS-2). We pooled data using random-effect diagnostic meta-analysis and relevant subgroup analyses were undertaken.

**Results:** 26 studies recruiting a total of 3979 patients were enrolled in this diagnostic meta-analysis. Pooled sensitivity (SSY), specificity (SPY), diagnostic odds ratio (DOR) and area under the receiver operating characteristic curve (AUROC) values were calculated per groups of NBI, HAL and 5-ALA in lesions or patient level. NBI showed significant diagnostic superiority compared with WLC in lesion level (SSY 0.94, 95% CI, 0.82-0.98; SPY 0.79, 95% CI, 0.73-0.85; DOR 40.09, 95% CI, 20.08-80.01; AUROC 0.88, 95% CI, 0.85-0.91). NBI presented highest DOR (358.71, 95% CI, 44.50-2891.71) in patient level. Subgroup analyses were performed on studies with low to moderate RoB and at least 100 patients at lesion level. These results showed consistency with those obtained in our overall analysis.

**Conclusions** Pooled data indicates image technique based transurethral resection (NBI, HAL and 5-ALA) show diagnostic superiority than WLC. Moreover, NBI could potentially be the most promising diagnostic intervention with best diagnostic performance outcomes. It is still needed to evaluate diagnostic and prognostic outcome of novel imaging technologies and WLC.

11 **Key words:** bladder cancer, diagnostic performance, Narrow band imaging, photodynamic diagnosis, white  
2  
3  
4 light-guided cystoscopy  
5  
6  
7

#### 8 **Strengths and limitations of this study** 9

- 10 ● This is the first systematic review and diagnostic meta-analysis exploring diagnostic accuracy of image  
11  
12 technique based transurethral resection compared with WLC.  
13  
14
- 15 ● Our study includes the stringent methodology used to synthesize the evidence obtained, such as  
16  
17 adhering to PRISMA guidelines, using standardized definitions of diagnostic performance analysis and  
18  
19 applying QUADAS-2 tool for RoB assessment.  
20  
21
- 22 ● The majority of studies had a low or moderate risk of bias. All studies clearly reported methodology  
23  
24 for the index test and reference standard, and were not considered a significant source of potential bias.  
25  
26
- 27 ● The further subgroup analysis was based on relatively few studies, but we used random-effect models  
28  
29 to compensate for clinical and methodological diversity among studies.  
30  
31
- 32 ● The lack of data on important clinical variables, such as grade and stage of disease, primary vs  
33  
34 recurrent disease and intravesical instillation settings, may introduce clinical heterogeneity and prevent  
35  
36 further subgroup analyses. We attempted to minimize biases by standardizing data extraction and  
37  
38 performing several subgroup analyses.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Bladder cancer is a prevalent malignancy with an estimated 80,470 newly diagnosed cases and 17,670 deaths in USA in 2019, among which about 75% of patients present with non-muscle invasive bladder cancer (NMIBC) <sup>1-3</sup>. Today, white light cystoscopy (WLC) is the gold-standard technique for detection of bladder cancer. However, the accuracy of WLC in detecting disease is unsatisfactory. The detection reliability of smaller tumors or carcinoma in situ (CIS) may be missed, which leads to that recurrence is remarkably common with up to 30% of patients having tumor identified at the first-check cystoscopy at 3 months and 50% of patients developing tumors within 12 months <sup>4,5</sup>. Thus, different optical imaging techniques have emerged as an adjunct to WLC to improve visualization of tumors by means of contrast enhancement.

Photodynamic diagnosis (PDD) is performed using blue-violet (380-440nm) light with intravesical instillation of 5-aminolevulinic acid (5-ALA) or hexaminolevulinic acid (HAL). The effect of 5-ALA induced fluorescence on tumor detection in the urinary bladder has been identified to be an efficient method of mapping the entire mucosa to detect urothelial tumors and flat CIS lesions <sup>6-8</sup>. HAL is the lipophilic hexylester of 5-ALA and has been commercially available since 2006, which has been established as the preferred intravesical agent for detection of NMIBC. However, intravesical inflammation leads to decreased specificity and pre-operative procedure contributed technical complexity and cost.

Narrow band imaging (NBI) is a new image-processing modality filtering white light down to two narrow band widths of 415 and 540 nm with advantage of avoiding the need for intravesical contrast administration <sup>9</sup>. Hemoglobin absorbs these wavelengths preferentially, which results in dark neovascularized bladder cancer strongly different from light background of normal mucosa. The superior diagnostic performance of NBI compared with WLC has been confirmed in several studies <sup>10-12</sup>. Overall, NBI yield a 9.9% increased detection rate on patient level and a 19.2% increase on lesion level in a recent meta-analysis, while subgroup

analysis showed NBI was associated with 53% reduction in recurrence rate at 3 months and 19% at 12 months compared with WLC<sup>13</sup>. Noticeably, NBI may be associated with increased false-positives, especially for patients with prior intravesical instillations<sup>14</sup>.

Although several studies demonstrated the diagnostic superiority of novel image technique-assisted transurethral resection. It is still uncertain which technique could better improve diagnosis accuracy of bladder cancer detection. In this study, the specific objective was to perform a systematic review and diagnosis meta-analysis assessing the diagnostic performance of PDD using 5-ALA, PDD using HAL, and NBI against the reference standard of WLC for NMIBC.

## Methods

The diagnostic meta-analysis was conducted based on the Meta-analysis of Observational Studies in Epidemiology statement<sup>15</sup>. All included studies were observational studies. When an included primary study did not match the Standards for Reporting of Diagnostic Accuracy statement, we gathered the information by the authors<sup>16</sup>.

### *Literature search*

All studies reporting the diagnostic performance of PDD with 5-ALA, PDD with HAL, or NBI, with WLC as reference standard, were retrieved from multiple databases including PubMed/MEDLINE, Web of Science, the Cochrane Library, Central Register of Controlled Trials and Embase up to 31<sup>st</sup> March 2018. The following MeSH free and combined terms which were adjusted for the different databases terms were used: “photodynamic diagnosis, PDD, hexaminolevulinate, HAL, 5-aminolevulinate acid, 5-ALA, narrow imaging, NBI, white light cystoscopy, urothelial cell carcinoma of bladder, transitional cell carcinoma, bladder cancer, bladder tumor and BCa”. The full search strategy was showed in Appendix (supplementary material). The review was performed according to Preferred Reporting Items for Systematic Reviews

(PRISMA)<sup>17</sup> and Standards for Reporting Diagnostic Accuracy Studies (STARD)<sup>18</sup>. The search was restricted to English-language publications. At least two reviewers (CHC and HH) screened all abstracts and full-text articles independently. Disagreement was resolved by consultation with an independent arbiter (JH).

### ***Inclusion and exclusion criteria***

Inclusion criteria included the following elements: 1) Population: Patients diagnosed with primary NMIBC, or patients previously diagnosed with NMIBC (recurrent tumors); 2) Reference standard: WLC must be provided as the reference standard for all patients, and the diagnosis of NMIBC was confirmed by histopathological examination; 3) studies reported data of intra-patient comparison. 4) Only the updated data was included in this study, when two or more studies provided data from the same institution during an overlapping time period.

Articles were excluded if the full-text article was not written in English. Abstracts, conference articles, historical overviews, case studies, reviews, and meta-analysis were not considered. Studies that failed to report on sensitivity and/or specificity data as compared with WLC were excluded. For missing or unclear data, we contacted the authors to get more information.

### ***Patient and Public Involvement***

Patients and public were not involved in this research.

### ***Study Quality***

The Quality Assessment of Diagnostic Studies-2 (QUADAS-2)<sup>19</sup> and the Strength Of Recommendation Taxonomy (SORT) numerical scale were applied on included studies<sup>20</sup>. Both checklists were performed independently by two authors (YZ and CHC); disagreement was resolved by consultation with an independent arbiter (JH). The “low RoB” was defined as at least 3 domains with “low” in both categories and without any domains evaluated “high” in either category; the “moderate RoB” was defined as



at least 2 domains with “low” in both categories and without any domain scoring “high” in either category;  
in addition to this was defined as “high” RoB.

### **Data Extraction**

The following data were extracted from the selected studies: 1) study characteristics (first author, study design, number of patients, follow-up); 2) intervention characteristics (index tests, duration of follow-up, schedule and nature of WLC); 3) patient characteristics (age, sex, NMIBC patients, tumor lesions); 4) diagnostic performance measure (sensitivity: SSY; specificity: SPY; negative predictive value: NPV; positive predictive value: PPV; false positive rate: FPR; false negative rate: FNR). Data was extracted from each study at lesion or patient level to assess 5-ALA, HAL and NBI as the index test using WLC as the reference standard, with positive or negative disease as determined by histopathological examination.

The Primary outcomes of SSY, SPY, NPV, PPV, FPR and FNR for individual studies were calculated with the following standard definitions. SSY was defined as the proportion of positive patients or lesions with index test in all cases of WLC-positive findings. SPY was defined as the proportion of negative patients or lesions with index test in all cases of WLC-negative findings. NPV was defined as the proportion of true negatives findings (both negative in index test and WLC) in all index test-negative cases or lesions; PPV was defined as the proportion of true positives findings (both positive in index test and WLC) in all index test-positive cases or lesions. FNR was defined as the proportion of index test-negative findings in all cases of WLC-positive cases or lesions; FPR was defined as the proportion of index test-positive findings in all cases of WLC-negative cases or lesions.

### **Statistical analysis**

Separate meta-analyses were performed for the currently new technology-assisted cystoscopy in NMIBC patients to best summarize the totality of the available evidence. The diagnostic meta-analysis was performed using Stata 13.0 (StataCorp, College Station, TX, USA) with metan and midas commands. A two-sided p

value of less than 0.05 was considered significant. In this study, a random-effect model was applied to quantify the pooled sensitivity, specificity, diagnostic odds ratio (DOR) and AUROC, with 95% confidence intervals (CIs) of the compared end points. DOR reflects the ability of a test to detect, a DOR of 1 indicates that the test has no discriminative power, the higher the DOR, the better the diagnostic ability of the new imaging technique. The AUROC is an overall summary measure index of the diagnostic accuracy. A perfect test will have an AUROC close to 1 and a poor test has AUROC close to 0.5<sup>21</sup>, which were plotted on Summary Receiver Operating Curve (SROC) using RevMan 5.2 software. We also formulated forest plots of the summary measures of accuracy and examined the heterogeneity of the summary measures of sensitivity and specificity. The publication bias was assessed using Deeks' funnel plot, and statistical significance was determined with Deeks' asymmetry test<sup>22 23</sup>. To explore the effect of heterogeneity on the results, subgroup analyses were planned based on disease grade (low grade vs high grade), stage (pTa vs pT1), setting (primary vs recurrent tumours), number of participants (studies with n>100 patients only), and on studies with low to moderate RoB.

## Results

### *Search and Study Selection*

The flow diagram summarizing the literature screening and inclusion process is presented in Figure 1. Of the 652 potentially relevant articles identified in the database search, 271 studies were excluded for duplication. We excluded 278 studies when screening titles and abstracts: 32 editorials or letters, 24 reviews or meeting abstracts, 85 non-comparative studies and 137 papers on an obviously different topic. During the screening of 103 full-text articles, 36 studies were excluded for not being relevant to this review and another 41 studies were excluded for not having within-patient comparisons. Finally, 26 studies<sup>12 24-48</sup> were included in the diagnostic meta-analysis.

## ***Study Demographics***

The characteristics of the 26 studies included in this meta-analysis are summarized in Table 1. The studies were published from 1994 to 2016 with sample size ranged from 12 to 605 patients. The mean or median age and the male/female ratio in the studies showed no differences. In 9 studies, the NBI diagnostic intervention was applied, while 5-ALA-based PDD was conducted in 9 studies, and HAL-based PDD in 8 studies. Most enrolled patients in included studies were NMIBC.

## ***Lesion level analysis***

All studies used non-standardized definitions to calculate their diagnostic outcomes, in which case the results of included studies were recalculated using standard definitions with the raw data provided (Supplementary Table 1). The diagnostic meta-analysis results were presented in lesion-level and patient-level analyses. Based on lesion level, the forest plot of estimates of DOR for NBI, HAL and 5-ALA compared with WLC were showed in Figure 2, the pooled DOR for NBI, HAL and 5-ALA were 40.09 (95% CI, 20.08-80.01, Figure 2A), 78.14 (95% CI, 31.42-194.28, Figure 2B) and 18.14 (95% CI, 4.28-76.87, Figure 2C). The SROC curves for NBI, HAL and 5-ALA were showed in Figure 3A, the AUROC of NBI, HAL and 5-ALA were 0.88 (95% CI, 0.85-0.91), 0.94 (95% CI, 0.92-0.96) and 0.82 (95% CI, 0.79-0.85). Importantly, the results of the SSY and SPY for each intervention are shown in Supplementary Figures 1-3. The pooled estimates for the SSY data for NBI, HAL and 5-ALA were 0.94 (95% CI, 0.82-0.98, Supplementary Figure 1A), 0.95 (95% CI, 0.91-0.98, Supplementary Figure 2A) and 0.90 (95% CI, 0.71-0.97, Supplementary Figure 3A), whereas the SPY data for NBI, HAL and 5-ALA were 0.79 (95% CI, 0.73-0.85, Supplementary Figure 1B), 0.81 (95% CI, 0.74-0.87, Supplementary Figure 2B) and 0.69 (95% CI, 0.57-0.79, Supplementary Figure 3B), presenting superiority compared with WLC. The DOR value and AUROC of NBI, HAL and 5-ALA presented excellent diagnostic performance.

## ***Patient level analysis***

11 As for patient level analysis, the AUROC, SSY and SPY could not be calculated as few studies  
12 included. Figure 2 showed the forest plots of DOR for NBI, HAL and 5-ALA. For NBI, the highest DOR  
13 were reached. The DOR for NBI and HAL were 358.71 (95% CI, 44.50-2891.71, Figure 2D) and 59.95  
14 (95% CI, 24.30-147.92, Figure 2E), present better performance compared with WLC. The SROC curves for  
15 NBI, HAL and 5-ALA were showed in Figure 3B. However, the DOR for 5-ALA was 79.52 (95% CI, 0.94-  
16 6759.92, Figure 2F), without statistic difference.

### 17 ***Subgroup Analysis***

18 Subgroup analyses were performed on studies with low to moderate RoB and at least 100 patients at  
19 lesion level. The diagnostic performance results for studies with low to moderate RoB and at least 100  
20 patients were demonstrated at Supplementary Table 2. The forest plot of estimates of pooled DOR for NBI,  
21 HAL and 5-ALA with low to moderate RoB were showed in Supplementary Figure 4; while forest plot of  
22 estimates of pooled DOR for NBI, HAL and 5-ALA with at least 100 patients were showed in  
23 Supplementary Figure 5. These results showed consistency with those obtained in our overall analysis.

### 24 ***RoB of included studies***

25 The comparison-adjusted funnel plots of the diagnostic meta-analysis were not suggestive of any  
26 publication bias, showed in Figure 4. QUADAS-2 tool was applied for RoB assessment of included studies  
27 in our meta-analysis (Supplementary Figure 6). Overall, all studies reported methodology for the index test  
28 and reference standard clearly without significant source of potential bias. 69% (18/26) of the studies were  
29 presented as low or unclear RoB across most domains. The risk of bias in the patient selection in 3 studies  
30 were deemed high due to the absence of consecutive inclusion of patients; 4 studies were at high RoBs for  
31 the flow and timing.

### 32 **Discussion**

11 Our systematic review indicated that pooled diagnostic performance of NBI, HAL or 5-ALA showed  
2  
3  
42 excellent efficacy compared with WLC. NBI could potentially be the most promising diagnostic  
5  
63 intervention for NMIBC patients with advantages in terms of simplicity, cost and reliability. In this study,  
7  
8  
94 we have summarized the diagnostic performance of new technique-assisted cystoscopy strategies for  
10  
11 NMIBC. Our diagnostic meta-analysis was further undertaken to estimate diagnostic performance of NBI,  
12  
13  
14 HAL and 5-ALA compared with WLC. Since virtually all of the techniques assessed in this review based  
15  
16  
17 on the reference standard of WLC, new technique-assisted cystoscopy showed diagnostic superiority than  
18  
19  
20 conventional WLC. In this context, adoption of these strategies in bladder cancer diagnosis practice is  
21  
22  
23 essential. The present results do strongly suggest that new imaging-based technologies, in particular NBI,  
24  
25  
26 are promising diagnostic intervention for bladder cancer detection in clinical practice.

27 Due to latent disadvantage of WLC, PDD and NBI have been recently developed to improve the  
28  
29  
30 visualization of bladder tumors. Diagnostic superiority of PDD or NBI over WLC have been demonstrated  
31  
32  
33 in several studies<sup>12 49 50</sup> for tumor detection. Further meta-analysis comparing PDD and WLC found a 21%  
34  
35  
36 increase in tumor detection with PDD in the pooled estimates for both patients and biopsies<sup>51</sup>. NBI, another  
37  
38  
39 optical enhancement technology, improve diagnostic accuracy by increasing contrast of superficial  
40  
41  
42 vasculature between normal mucosa and tumor tissue. Previous studies reported significant detection  
43  
44  
45 improvement in bladder tumors with NBI cystoscopy compared with standard WLC<sup>12 14</sup>. Our former meta-  
46  
47  
48 analysis indicated that NBI provides an additional 17% of patients and an additional 24% of tumors  
49  
50  
51 compared with WLC<sup>52</sup>. However, these studies did not use standardized diagnostic accuracy definitions.  
52  
53  
54 Our diagnostic meta-analysis applied standard diagnostic accuracy definitions and further pooled estimates  
55  
56  
57 demonstrated new technique assisted cystoscopy showed significant diagnostic superiority than  
58  
59  
60 conventional WLC, demonstrating the sub-optimal performance of WLC in diagnosing NMIBC.

Study performed by Burger<sup>53</sup> showed that PDD using HAL significantly reduced recurrence rate at 9–12

11 months compared with WLC-assisted TUR alone. Also, Lee et al performed a meta-analysis<sup>54</sup> evaluating  
2  
3  
42 oncologic outcomes for WLC, PDD- and NBI-assisted TUR, which showed both PDD and NBI reduced  
5  
63 recurrence rate compared with WLC. However, therapeutic effectiveness of new technique assisted TUR  
7  
8  
94 such as recurrence and progression could not be demonstrated in this review. Future therapeutic efficacy  
10  
11 analysis was needed to identify promising intervention.  
12

14 The strengths of our study include the stringent methodology used to rigorous search and study inclusion  
15  
16 procedure, standard definition of diagnostic performance and data extraction, strict diagnostic meta-  
17  
18 analysis, specific QUADAS-2 tool for RoB assessment. Moreover, the strict diagnostic meta-analysis and  
19  
20 further subgroup analysis was applied to synthesize diagnostic accuracy for reliable result. However,  
21  
22 potential study limitations should be acknowledged. The lack of data on important clinical variables, such  
23  
24 as grade and stage of disease, primary vs recurrent disease and intravesical instillation settings, may  
25  
26 introduce clinical heterogeneity and prevent further subgroup analyses. And predictive performance of  
27  
28 recurrence or progression was not demonstrated in our study, which may decrease the reliability of  
29  
30 diagnostic performance. We have attempted to minimize biases throughout the whole procedure, with  
31  
32 rigorous search and selection criteria, standard data extraction and re-calculation, subgroup analysis  
33  
34 application, to evaluate the robustness of our findings.  
35  
36  
37  
38  
39  
40  
41

42 In summary, this meta-analysis provides pooled diagnostic accuracy for NBI, HAL and 5-ALA  
43  
44 techniques for NMIBC patients compared with WLC as a reference standard. The results demonstrate that  
45  
46 diagnostic performance of NBI, HAL and 5-ALA all show superiority than WLC at lesion level in  
47  
48 diagnostic meta-analysis. The findings demonstrate the superior diagnostic performance of new imaging  
49  
50 technique in bladder detection compared with conventional WLC. New imaging technique are promising  
51  
52 diagnostic intervention improving clinical procedure in bladder cancer detection in the future.  
53  
54  
55  
56  
57  
58  
59  
60

**Abbreviations** CI: Confidence intervals; CIS: carcinoma in situ; DOR: Diagnostic odds ratios; DTA: Diagnostic test accuracy; FNR: False negative rate; FPR: False positive rate; IQR: Interquartile range; HAL: hexylaminolevulinate; NBI: and narrow band imaging; NMIBC: Non-muscle-invasive bladder cancer; NPV: Negative predictive value; PDD: Photodynamic diagnosis; PPV: Positive predictive value; SPY: Specificity; SSY: Sensitivity; SROC: Summary receiver operating curve; AUROC: Area under the receiver operating characteristic curve; TURBT: Transurethral resection of bladder tumors; WLC: White light cystoscopy; 5-ALA: 5-aminolaevulinic acid.

**Acknowledgements** We would like to thank Prof. J.X. Zhang, Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, China, for statistical advice and research comments.

**Contributors** CHC conceptualized and designed the study, drafted the initial and final manuscript, provided funding support. HH contributed to data collection and extraction, data analysis and interpretation, drafted initial and final manuscript. YZ contributed to article screening, data collection and extraction, assessment of risk of bias and drafting manuscript: HL contributed to article screening, data collection and extraction and assessment of risk of bias. RJ Sylvester led and supervised statistical analysis, provided administrative support. TXL and JH contributed to study conceptualization and design, supervised study implementation, and critically reviewed the manuscript.

**Funding** This study was funded by the National Natural Science Foundation of China (Grant No. 81572514, 81472384, 81472381, 81402106, 81772719, 81772728, 91740119, 91529301); Guangdong Medical Research Fund (A2018330); Science and Technology Program of Guangzhou (Grant No. 201604020156, 201604020177, 201707010116, 201803010098); National Natural Science Foundation



1 of Guangdong (Grant No. 2018A030313564, 2018B030311009, 2018A030310250,2016A030313321,  
2 2015A030311011, 2015A030310122). Yixian Youth project of Sun Yat-sen Memorial Hospital  
3 (YXQH201812).  
4  
5  
6  
7  
8  
9  
10

11 **Competing interests** None declared.  
12  
13  
14  
15

16 **Patient consent** Not required.  
17  
18  
19  
20

21 **Provenance and peer review** Not commissioned; externally peer reviewed.  
22  
23  
24  
25

26 **Data sharing statement** All data relevant to the study are included in the article or uploaded as  
27 supplementary information.  
28  
29  
30

## 31 **References**

32  
33  
34

- 35 1. Antoni S, Ferlay J, Soerjomataram I, et al. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.  
36 *European urology* 2016 doi: 10.1016/j.eururo.2016.06.010  
37
- 38 2. Babjuk M, Bohle A, Burger M, et al. Guidelines on non-muscle-invasive bladder cancer (Ta,T1 and CIS). European Association  
39 of Urology Web site. <http://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/>.  
40
- 41 3. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the  
42 2011 update. *European urology* 2011;59(6):997-1008. doi: 10.1016/j.eururo.2011.03.017 [published Online First:  
43 2011/04/05]  
44
- 45 4. Schwaibold HE, Sivalingam S, May F, et al. The value of a second transurethral resection for T1 bladder cancer. *BJU international*  
46 2006;97(6):1199-201. doi: 10.1111/j.1464-410X.2006.06144.x  
47
- 48 5. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage  
49 Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. *European*  
50 *urology* 2006;49(3):466-5; discussion 75-7. doi: 10.1016/j.eururo.2005.12.031  
51
- 52 6. Grimbergen MCM, van Swol CFP, Jonges TGN, et al. Reduced Specificity of 5-ALA Induced Fluorescence in Photodynamic  
53 Diagnosis of Transitional Cell Carcinoma after Previous Intravesical Therapy. *European urology* 2003;44(1):51-56. doi:  
54 10.1016/s0302-2838(03)00210-0  
55
- 56 7. Danilchenko DI, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral  
57 resection of superficial bladder cancer: 5-year results of a prospective randomized study. *The Journal of urology*  
58 2005;174(6):2129-33, discussion 33. doi: 10.1097/01.ju.0000181814.73466.14  
59
- 60 8. Kriegmair M, Baumgartner R, Knuchel R, et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin  
fluorescence. *The Journal of urology* 1996;155(1):105-9; discussion 09-10. [published Online First: 1996/01/01]



- 1 9. Bryan RT, Shah ZH, Collins SI, et al. Narrow-band imaging flexible cystoscopy: a new user's experience. *Journal of endourology*  
2 2010;24(8):1339-43. doi: 10.1089/end.2009.0598 [published Online First: 2010/07/16]
- 33 10. Naito S, Algaba F, Babjuk M, et al. The Clinical Research Office of the Endourological Society (CROES) Multicentre  
44 Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus  
5 Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial  
6 Protocol and 1-year Results. *European urology* 2016 doi: 10.1016/j.eururo.2016.03.053
- 87 11. Naselli A, Introini C, Timossi L, et al. A randomized prospective trial to assess the impact of transurethral resection in narrow  
9 band imaging modality on non-muscle-invasive bladder cancer recurrence. *European urology* 2012;61(5):908-13. doi:  
10 10.1016/j.eururo.2012.01.018
- 12 12. Ye Z, Hu J, Song X, et al. A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A  
13 prospective, randomized and multi-center study. *Scientific reports* 2015;5:10905. doi: 10.1038/srep10905
- 14 13. Xiong Y, Li J, Ma S, et al. A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle  
15 invasive bladder cancer. *PloS one* 2017;12(2):e0170819. doi: 10.1371/journal.pone.0170819 [published Online First:  
16 2017/02/14]
- 17 14. Geavlete B, Multescu R, Georgescu D, et al. Narrow band imaging cystoscopy and bipolar plasma vaporization for large  
18 nonmuscle-invasive bladder tumors--results of a prospective, randomized comparison to the standard approach. *Urology*  
19 2012;79(4):846-51. doi: 10.1016/j.urology.2011.08.081
- 22 15. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-  
23 analysis Of Observational Studies in Epidemiology (MOOSE) group. *Jama* 2000;283(15):2008-12.
- 26 16. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the  
27 STARD initiative. *BMJ* 2003;326(7379):41-4.
- 28 17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.  
29 *Int J Surg* 2010;8(5):336-41. doi: 10.1016/j.ijisu.2010.02.007 [published Online First: 2010/02/23]
- 30 18. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy  
31 studies. *BMJ* 2015;351:h5527. doi: 10.1136/bmj.h5527 [published Online First: 2015/10/30]
- 32 19. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy  
33 studies. *Annals of internal medicine* 2011;155(8):529-36. doi: 10.7326/0003-4819-155-8-201110180-00009 [published  
34 Online First: 2011/10/19]
- 35 20. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading  
36 evidence in the medical literature. *Am Fam Physician* 2004;69(3):548-56.
- 39 21. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology*  
40 1982;143(1):29-36. doi: 10.1148/radiology.143.1.7063747 [published Online First: 1982/04/01]
- 41 22. Song F, Khan KS, Dinnes J, et al. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. *Int J*  
42 *Epidemiol* 2002;31(1):88-95. [published Online First: 2002/03/27]
- 44 23. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews  
45 of diagnostic test accuracy was assessed. *J Clin Epidemiol* 2005;58(9):882-93. doi: 10.1016/j.jclinepi.2005.01.016  
46 [published Online First: 2005/08/09]
- 47 24. Zhu YP, Shen YJ, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of clinically unconfirmed positive  
48 urine cytology. *Urologia internationalis* 2012;88(1):84-7. doi: 10.1159/000333119
- 49 25. Zaak D, Kriegmair M, Stepp H, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of  
50 1012 fluorescence endoscopies. *Urology* 2001;57(4):690-4. [published Online First: 2001/04/18]
- 51 26. Tatsugami K, Kuroiwa K, Kamoto T, et al. Evaluation of narrow-band imaging as a complementary method for the detection of  
52 bladder cancer. *Journal of endourology / Endourological Society* 2010;24(11):1807-11. doi: 10.1089/end.2010.0055  
53 [published Online First: 2010/08/17]
- 54 27. Song PH, Cho S, Ko YH. Decision Based on Narrow Band Imaging Cystoscopy without a Referential Normal Standard Rather  
55 Increases Unnecessary Biopsy in Detection of Recurrent Bladder Urothelial Carcinoma Early after Intravesical Instillation.  
56 *Cancer Res Treat* 2016;48(1):273-80. doi: 10.4143/crt.2014.190

- 1 28. Shen YJ, Zhu YP, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive  
2 bladder cancer: a "second look" matters? *International urology and nephrology* 2012;44(2):451-7. doi: 10.1007/s11255-  
3 011-0036-5
- 4 29. Shadpour P, Emami M, Haghdani S. A Comparison of the Progression and Recurrence Risk Index in Non-Muscle-Invasive  
5 Bladder Tumors Detected by Narrow-Band Imaging Versus White Light Cystoscopy, Based on the EORTC Scoring  
6 System. *Nephrourol Mon* 2016;8(1):e33240. doi: 10.5812/numonthly.33240
- 7 30. Schmidbauer J, Remzi M, Klatte T, et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging  
8 as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. *European urology*  
9 2009;56(6):914-9. doi: 10.1016/j.eururo.2009.07.042
- 10 31. Riedl CR, Plas E, Pfluger H. Fluorescence detection of bladder tumors with 5-amino-levulinic acid. *Journal of endourology /*  
11 *Endourological Society* 1999;13(10):755-9. doi: 10.1089/end.1999.13.755 [published Online First: 2000/01/26]
- 12 32. Ray ER, Chatterton K, Khan MS, et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with  
13 intravesical bacille Calmette-Guerin. *BJU international* 2010;105(6):789-94. doi: 10.1111/j.1464-410X.2009.08839.x
- 14 33. Palou J, Hernandez C, Solsona E, et al. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-  
15 muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study. *BJU international*  
16 2015;116(1):37-43. doi: 10.1111/bju.13020
- 17 34. Lapini A, Minervini A, Masala A, et al. A comparison of hexaminolevulinate (Hexvix((R))) fluorescence cystoscopy and white-  
18 light cystoscopy for detection of bladder cancer: results of the HeRo observational study. *Surg Endosc* 2012;26(12):3634-  
19 41. doi: 10.1007/s00464-012-2387-0
- 20 35. Kobatake K, Mita K, Ohara S, et al. Advantage of transurethral resection with narrow band imaging for non-muscle invasive  
21 bladder cancer. *Oncol Lett* 2015;10(2):1097-102. doi: 10.3892/ol.2015.3280
- 22 36. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis  
23 of superficial bladder cancer--a multicenter study. *The Journal of urology* 2003;170(1):226-9. doi:  
24 10.1097/01.ju.0000060782.52358.04
- 25 37. Jeon SS, Kang I, Hong JH, et al. Diagnostic efficacy of fluorescence cystoscopy for detection of urothelial neoplasms. *Journal*  
26 *of endourology / Endourological Society* 2001;15(7):753-9. doi: 10.1089/08927790152596370 [published Online First:  
27 2001/11/08]
- 28 38. Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour  
29 recurrences. *BJU international* 2008;102(9):1111-4. doi: 10.1111/j.1464-410X.2008.07846.x
- 30 39. Grimbergen MC, van Swol CF, Jonges TG, et al. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis  
31 of transitional cell carcinoma after previous intravesical therapy. *European urology* 2003;44(1):51-6. [published Online  
32 First: 2003/06/20]
- 33 40. Geavlete B, Multescu R, Georgescu D, et al. Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the  
34 bladder in noninvasive bladder tumors. *Journal of endourology / Endourological Society* 2009;23(6):977-81. doi:  
35 10.1089/end.2008.0574 [published Online First: 2009/05/29]
- 36 41. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light  
37 cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. *The Journal*  
38 *of urology* 2007;178(1):68-73; discussion 73. doi: 10.1016/j.juro.2007.03.028
- 39 42. Filbeck T, Roessler W, Knuechel R, et al. Clinical results of the transurethral resection and evaluation of superficial bladder  
40 carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. *Journal of*  
41 *endourology / Endourological Society* 1999;13(2):117-21. doi: 10.1089/end.1999.13.117 [published Online First:  
42 1999/04/23]
- 43 43. Filbeck T, Pichlmeier U, Knuechel R, et al. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in  
44 transurethral resection of bladder carcinoma? *Urology* 2002;60(6):1025-8. [published Online First: 2002/12/12]
- 45 44. Ehsan A, Sommer F, Haupt G, et al. Significance of fluorescence cystoscopy for diagnosis of superficial bladder cancer after  
46 intravesical instillation of delta aminolevulinic acid. *Urologia internationalis* 2001;67(4):298-304. [published Online First:  
47 2001/12/13]

- 1 45. De Dominicis C, Liberti M, Perugia G, et al. Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder  
2 cancer: improvement in diagnostic sensitivity. *Urology* 2001;57(6):1059-62. [published Online First: 2001/05/30]
- 3 46. D'Hallewin MA, Vanherzeele H, Baert L. Fluorescence detection of flat transitional cell carcinoma after intravesical instillation  
4 of aminolevulinic acid. *American journal of clinical oncology* 1998;21(3):223-5. [published Online First: 1998/06/17]
- 5 47. Cauberg EC, Kloen S, Visser M, et al. Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder  
6 cancer. *Urology* 2010;76(3):658-63. doi: 10.1016/j.urology.2009.11.075
- 7 48. Burgues JP, Conde G, Oliva J, et al. [Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer:  
8 experience of the BLUE group]. *Actas urologicas espanolas* 2011;35(8):439-45. doi: 10.1016/j.acuro.2011.03.003  
9 [published Online First: 2011/05/31]
- 10 49. Babjuk M, Soukup V, Petrik R, et al. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection  
11 reduces the risk of recurrence in stage Ta/T1 bladder cancer. *BJU international* 2005;96(6):798-802. doi: 10.1111/j.1464-  
12 410X.2004.05715.x [published Online First: 2005/09/13]
- 13 50. Gkritisios P, Hatzimouratidis K, Kazantzidis S, et al. Hexaminolevulinate-guided transurethral resection of non-muscle-invasive  
14 bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial. *International*  
15 *urology and nephrology* 2014;46(5):927-33. doi: 10.1007/s11255-013-0603-z
- 16 51. Mowatt G, N'Dow J, Vale L, et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic  
17 review and meta-analysis. *International journal of technology assessment in health care* 2011;27(1):3-10. doi:  
18 10.1017/S0266462310001364
- 19 52. Li K, Lin T, Fan X, et al. Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and  
20 meta-analysis. *International journal of urology : official journal of the Japanese Urological Association* 2013;20(6):602-  
21 9. doi: 10.1111/j.1442-2042.2012.03211.x
- 22 53. Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with  
23 hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. *Eur Urol* 2013;64(5):846-  
24 54. doi: 10.1016/j.eururo.2013.03.059
- 25 54. Lee JY, Cho KS, Kang DH, et al. A network meta-analysis of therapeutic outcomes after new image technology-assisted  
26 transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs  
27 hexylaminolevulinate fluorescence vs narrow band imaging. *BMC cancer* 2015;15:566. doi: 10.1186/s12885-015-1571-8
- 28 55. Burgues JP, Conde G, Oliva J, et al. [Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer:  
29 experience of the BLUE group]. *Actas urologicas espanolas* 2011;35(8):439-45. doi: 10.1016/j.acuro.2011.03.003  
30 [published Online First: 2011/05/31]
- 31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

11 **Figure legend**

2  
3  
42 **Figure 1.** The PRISMA flow chart of included studies in DTA analysis.

5  
63 **Figure 2.** The Forest Plot of estimates of DOR for NBI (A), HAL (B), 5-ALA (C) in lesion level and  
7  
8 estimates of DOR for NBI (D), HAL (E), 5-ALA (F) in patient level.

10  
11 **Figure 3.** The SROC curve for NBI, HAL and 5-ALA diagnosing NMIBC in lesion level (A) and patient  
12  
13 level (B).

14  
15  
16 **Figure 4.** Deeks' funnel plot with asymmetry test for NBI (A), HAL (B) and 5-ALA (C) in lesion level.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1 Summary of the characteristics of the included studies**

Study	Institution No.	patients	Index test	period	Age, mean (range)	Male (%)	NMIBC (%)	Tumor lesions (n)
<b>NBI vs WLC</b>								
Shadpour et al.2016 <sup>29</sup>	Unicentre, Observational	50	NBI	2012-2013	63.86 ± 10.05	34(68.0)	100	95
Song et al.2016 <sup>27</sup>	Unicentre, Observational	63	NBI	2012-2013	66(56-76)	39(61.9)	94.1	21
Kobotake et Al.2015 <sup>35</sup>	Unicentre, Observational	135	NBI	2010-2014	75	110(81.5)	100	120
Ye et al.2015 <sup>12</sup>	Multicentre, Observational	384	NBI	NR	61(21-79)	267(69.5)	100	167
Shen et al.2012 <sup>28</sup>	Unicentre, Observational	78	NBI	2009-2010	68 (33–75)	62(79.5)	100	211
Zhu et al. 2012 <sup>24</sup>	Unicentre, Observational	12	NBI	2009-2010	57(28-73)	9(75.0)	100	9
Tatsugami et Al.2010 <sup>26</sup>	Unicentre, Observational	104	NBI	2007-2009	70.6 (38-90)	88(84.6)	NR	110
Cauberg et Al.2009 <sup>47</sup>	Multicentre, Observational	95	NBI	2007-2009	70.6 (38.1-90.2)	70(73.7)	NR	226
Herr et Al.2008 <sup>38</sup>	Unicentre, Observational	427	NBI	2007	65 (26-90)	316(74.0)	100	NR
<b>HAL vs WLC</b>								
Palou et Al.2014 <sup>33</sup>	Multicentre, Observational	283	HAL	2008-2009	67.5(42-95)	242(85.5)	94.1	621
Lapini et Al.2012 <sup>34</sup>	Multicentre, Observational	96	HAL	2010-2011	NR	80(83.3)	NR	108
Burgues et Al.2011 <sup>55</sup>	Multicentre, Observational	305	HAL	2006-2009	66.9(39-93)	270(88.5)	100	600
Ray et al.2010 <sup>32</sup>	Unicentre, Observational	27	HAL	2005-2006	70(49-82)	21(77.8)	100	NR
Schmidbauer et al.2009 <sup>30</sup>	Unicentre, Observational	66	HAL	NR	63(38-84)	49(74.2)	93.1	NR
Geavlete et Al.2008 <sup>40</sup>	Unicentre, Observational	128	HAL	2007-2008	65(36-81)	NR	92.2	NR
Fradet et Al.2006 <sup>41</sup>	Multicentre, Observational	298	HAL	NR	67±11	223(74.8)	100	113
Jichlinski et Al.2003 <sup>36</sup>	Multicentre, Observational	52	HAL	2000-2001	72±12	38(73.1)	100	143
<b>5-ALA vs WLC</b>								
Grimbergen et Al.2003 <sup>6</sup>	Unicentre, Observational	160	5-ALA	1998-2002	67(30-91)	NR	90.0%	390
Filbeck et Al.2002 <sup>43</sup>	Unicentre, Observational	279	5-ALA	1997-2000	34-89	NR	90.3%	336
Dominicis et	Unicentre,	49	5-ALA	NR	60(31-77)	42(85.7)	100	52

1	Al.2001 <sup>45</sup>	Observational							
2	Ehsan et	Unicentre,	30	5-ALA	NR	55-89	19(63.3)	NR	NR
3	Al.2001 <sup>44</sup>	Observational							
4	Jeon at	Unicentre,	62	5-ALA	1997-1999	61.9(32-80)	57(91.1)	NR	148
5	Al.2001 <sup>37</sup>	Observational							
6	Zaak et	Unicentre,	605	5-ALA	NR	65.6(16-99)	472(78.0)	NR	552
7	Al.2001 <sup>25</sup>	Observational							
8	Filbeck et	Unicentre,	123	5-ALA	1997	64.5(28-86)	NR	91.9	124
9	Al.1999 <sup>42</sup>	Observational							
10	Riedl et	Unicentre,	52	5-ALA	NR	44-79	NR	100	123
11	Al.1999 <sup>31</sup>	Observational							
12	D'hallewin et	Unicentre,	16	5-ALA	NR	NR	NR	100	50
13	Al.1998 <sup>46</sup>	Observational							

17 WLC: white light cystoscopy; NT: new technology; 5-ALA: 5-aminolaevulinic acid; HAL: hexylaminolevulinate; NBI: narrow  
 18 band imaging; NR: not reported.  
 19




Figure 1. The PRISMA flow chart of included studies in DTA analysis.

177x108mm (300 x 300 DPI)






Figure 2. The Forest Plot of estimates of DOR for NBI (A), HAL (B), 5-ALA (C) in lesion level and estimates of DOR for NBI (D), HAL (E), 5-ALA (F) in patient level.

177x180mm (300 x 300 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3. The SROC curve for NBI, HAL and 5-ALA diagnosing NMIBC in lesion level (A) and patient level (B).

177x94mm (300 x 300 DPI)






Figure 4. Deeks' funnel plot with asymmetry test for NBI (A), HAL (B) and 5-ALA (C) in lesion level.

177x147mm (300 x 300 DPI)


## Supplementary Information



**Supplementary Figure 1.** The Forest Plot of study specific and pooled sensitivity (A) and specificity (B) for NBI in lesion level.




**Supplementary Figure 2.** The Forest Plot of study specific and pooled sensitivity (A) and specificity (B) for HAL in lesion level.




**Supplementary Figure 3.** The Forest Plot of study specific and pooled sensitivity (A) and specificity (B) for 5-ALA in lesion level.


A




B




C



Supplementary Figure 4. The Forest Plot of estimates of DOR for NBI (A), HAL (B) and 5-ALA (C) with low to moderate RoB in lesion level.



**Supplementary Figure 5.** The Forest Plot of estimates of DOR for NBI (A), HAL (B) and 5-ALA (C) with at least 100 patients in lesion level.



**Supplementary Figure 6.** Quality assessment of included studies. The distribution plot for risk of bias using QUADAS-2 tool. Studies are deemed to be at high, low or unclear risk of bias for each domain.

For peer review only



**Supplementary Table 1. Diagnostic performance results of individual studies for Meta-analysis**

Study ID	Patient-level analysis							Lesion-level analysis						
	Patient No.	SSY	SPY	FP R	FN R	PP V	NP V	Lesion No.	SSY	SPY	FPR	FN R	PP V	NP V
<b>NBI vs WLC</b>														
Shadpour et al.2016 <sup>1</sup>	50	NR	NR	NR	NR	NR	NR	175	69/80	70/85	15/85	11/80	69/84	74/75
Song et al.2016 <sup>2</sup>	63	16/16	46/47	1/47	0/1	16/16	23/23	66	19/19	45/47	2/47	0/1	19/21	7/7
Kobota et al.2015 <sup>3</sup>	135	NR	NR	NR	NR	NR	NR	379	78/84	227/263	36/63	6/8	78/14	203/203
Ye et al.2015 <sup>4</sup>	103	56/56	16/45	29/46	0/5	56/85	8/8	300	124/126	92/33	41/33	2/26	124/165	83/5
Shen et al.2012 <sup>5</sup>	78	47/47	9/22	13/22	0/4	47/47	7/7	309	160/160	98/34	36/34	0/60	160/196	72/2
Zhu et al.2012 <sup>6</sup>	12	NR	NR	NR	NR	NR	NR	31	4/6	19/22	3/22	2/6	4/7	20/20
Tatsugami et al.2010 <sup>7</sup>	104	NR	NR	NR	NR	NR	NR	313	55/63	156/203	47/203	8/6	55/102	144/144
Cauberg et al.2009 <sup>8</sup>	95	NR	NR	NR	NR	NR	NR	389	167/179	116/163	47/63	12/179	167/214	47/51
Herr et al.2008 <sup>9</sup>	427	90/90	311/324	13/24	0/90	90/103	265/265	NR	NR	NR	NR	NR	NR	NR
<b>HAL vs WLC</b>														
Palou et al.2014 <sup>10</sup>	283	NR	NR	NR	NR	NR	NR	1492	379/416	820/948	128/948	37/416	379/507	699/702
Lapini et al.2012 <sup>11</sup>	96	NR	NR	NR	NR	NR	NR	234	82/83	101/126	25/26	1/8	82/107	80/81
Burgues et al.2011 <sup>12</sup>	305	NR	NR	NR	NR	NR	NR	1659	404/441	900/1059	159/1059	7/41	404/563	863/863

1	<b>Ray et</b>	27	NR	NR	NR	NR	NR	NR	120	21/2	84/9	10/9	0/2	21/3	35/3
2	<b>al.2010<sup>1</sup></b>									1	4	4	1	1	5
3	<b>3</b>														
4	<b>Schmid</b>	66	52/5	2/8	6/8	0/5	52/5	3/3	364	109/	151/	50/2	4/1	109/	158/
5	<b>bauer</b>		2			2	8			113	201	01	13	159	158
6	<b>et</b>														
7	<b>al.2009<sup>1</sup></b>														
8	<b>4</b>														
9	<b>Geavlet</b>	128	NR	NR	NR	NR	NR	NR	243	87/9	56/1	47/1	6/9	87/1	76/8
10	<b>e et</b>									3	03	03	3	34	2
11	<b>al.2008<sup>1</sup></b>														
12	<b>5</b>														
13	<b>Fradet</b>	196	40/4	128/	10/1	8/4	40/5	106/	206	77/8	101/	11/11	6/8	77/8	63/7
14	<b>et</b>		8	138	38	8	0	113		3	112	2	3	8	1
15	<b>al.2006<sup>1</sup></b>														
16	<b>6</b>														
17	<b>Jichlins</b>	52	33/3	7/17	10/1	0/3	33/4	3/3	143	205/	269/	74/3	49/	205/	306/
18	<b>ki et</b>		3		7	3	3			254	343	43	254	279	314
19	<b>al.2003<sup>1</sup></b>														
20	<b>7</b>														
21	<b>5-ALA</b>														
22	<b>vs</b>														
23	<b>WLC</b>														
24	<b>Grimbe</b>	160	NR	NR	NR	NR	NR	NR	889	232/	409/	118/	12/	232/	248/
25	<b>rgen et</b>									244	527	527	244	350	257
26	<b>al.2003<sup>1</sup></b>														
27	<b>8</b>														
28	<b>Filbeck</b>	279	168/	93/1	9/10	0/1	168/	81/8	NR	NR	NR	NR	NR	NR	NR
29	<b>et</b>		168	02	2	68	177	1							
30	<b>al.2002<sup>1</sup></b>														
31	<b>9</b>														
32	<b>Domini</b>	49	NR	NR	NR	NR	NR	NR	179	2/9	84/1	43/1	7/9	2/45	80/8
33	<b>cis et</b>										27	27			0
34	<b>al.2001<sup>2</sup></b>														
35	<b>0</b>														
36	<b>Ehsan</b>	30	NR	NR	NR	NR	NR	NR	151	39/4	71/9	20/9	1/4	39/5	59/5
37	<b>et</b>									0	1	1	0	9	9
38	<b>al.2001<sup>2</sup></b>														
39	<b>1</b>														
40	<b>Jeon at</b>	62	NR	NR	NR	NR	NR	NR	257	71/7	69/1	57/1	3/7	71/1	54/5
41	<b>al.2001<sup>2</sup></b>									4	26	26	4	28	4
42	<b>2</b>														
43	<b>Zaak et</b>	605	288/	271/	189/	75/	288/	55/1	NR	NR	NR	NR	NR	NR	NR
44	<b>al.2001<sup>2</sup></b>		363	460	460	363	477	08							
45	<b>3</b>														
46	<b>Filbeck</b>	123	NR	NR	NR	NR	NR	NR	341	75/8	185/	38/2	5/8	75/1	78/7
47	<b>et</b>									0	223	23	0	13	8

1 **al.1999<sup>2</sup>**

2 4

3 **Riedl et** 52 26/2 10/1 8/18 0/2 26/3 6/6 NR NR NR NR NR NR NR

4 **al.1999<sup>2</sup>** 6 8 6 4

5 5

6 **D'Halle** 16 NR NR NR NR NR NR NR 113 11/1 27/6 36/6 3/1 11/4 34/3

7 **win et** 4 3 3 4 7 4

8 **al.1998<sup>2</sup>**

9 6

10

11

---

12 NMIBC: non-muscle-invasive bladder cancer; WLC: white light cystoscopy; 5-ALA: 5-aminolaevulinic  
 13 acid; HAL: hexylaminolevulinate; NBI: narrow band imaging; NT: new technology; SSY: sensitivity; SPY:  
 14 specificity; FPR: false positive rate; FNR: false negative rate; PPV: positive predictive value; NPV: negative  
 15 predictive value; NR: not reported.

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

**Supplementary Table2. Diagnostic performance results for sensitivity analysis of studies with low to moderate RoB and at least 100 patients at lesion level.**

	Low to moderate RoB			At least 100 patients		
	Median	Lower Quartile	Upper Quartile	Median	Lower Quartile	Upper Quartile
<b>NBI vs WLC (n=6)</b>	<b>NBI vs WLC (n=3)</b>					
Sensitivity	95.85	88.80	99.60	92.86	90.08	95.63
Specificity	74.99	71.66	80.98	76.85	73.01	81.58
Positive predictive value	79.84	75.87	82.02	68.42	61.17	71.79
Negative predictive value	99.33	97.90	100	100	98.82	100
False positive rate	25.01	19.02	28.34	23.15	18.42	26.99
False negative rate	4.15	0.40	11.20	7.14	4.37	9.92
<b>HAL vs WLC (n=6)</b>	<b>HAL vs WLC (n=4)</b>					
Sensitivity	95.00	92.97	98.21	92.19	91.48	92.97
Specificity	83.33	76.38	88.65	85.74	77.33	87.42
Positive predictive value	71.65	67.94	76.16	73.26	70.05	77.94
Negative predictive value	99.17	94.20	99.89	96.13	91.70	99.68
False positive rate	16.67	11.35	23.62	14.26	12.58	22.67
False negative rate	5.00	1.79	7.03	6.84	5.24	7.65
<b>5-ALA vs WLC (n=4)</b>	<b>5-ALA vs WLC (n=2)</b>					
Sensitivity	95.51	94.75	96.33	94.42	-	-
Specificity	77.82	71.90	79.26	80.28	-	-
Positive predictive value	66.19	63.44	66.31	66.33	-	-
Negative predictive value	100	99.12	100	98.25	-	-
False positive rate	22.18	20.74	28.10	19.72	-	-
False negative rate	4.49	3.67	5.25	5.58	-	-

NMIBC: non-muscle-invasive bladder cancer; WLC: white light cystoscopy; 5-ALA: 5-aminolaevulinic acid; HAL: hexylaminolevulinate; NBI: narrow band imaging; NR: not reported.

**Appendix: Full search strategy**

## 1. Searching in MEDLINE, Embase and CENTRAL

All databases were searched using both controlled vocabulary (namely MeSH in MEDLINE and Emtree in Embase) and a wide range of free-text terms

Search code for MEDLINE (accessed via PubMed) and CENTRAL

<b>Patients</b>		
Bladder cancer	#1	bladder neoplasms [MeSH] OR carcinoma OR tumor, urothelial cell [MeSH] OR transitional cell carcinoma*[tiab] OR bladder neoplasm*[tiab] OR bladder cancer[tiab] OR BCa[tiab]
<b>Index test</b>		
Photodynamic diagnosis	#2	“photodynamic diagnosis” [MeSH] OR “PDD” [tiab] OR “photodynamic” [tiab] OR hexaminolevulinate [tiab] OR HAL[tiab] OR “5-aminolevulinate acid”[tiab] OR 5-ALA[tiab] OR cystoscopic[tiab] OR cystoscopy
Narrow band imaging	#3	“narrow band imaging” [MeSH] OR NBI [tiab] OR cystoscopic[tiab] OR cystoscopy[tiab]
Cochrane Highly Sensitive Search Strategy	#4	(observational trial[Publication Type] OR diagnostic[Publication Type] OR detection[tiab] OR observational[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT humans[mh])
Search algorithm		#1 AND (#2 OR #3) AND #4

## 2. Searching other resources

Previous systematic reviews in the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effectiveness and the PROSPERO international prospective register of systematic reviews for completed or published systematic reviews

## References

1. Shadpour P, Emami M, Haghani S. A Comparison of the Progression and Recurrence Risk Index in Non-Muscle-Invasive Bladder Tumors Detected by Narrow-Band Imaging Versus White Light Cystoscopy, Based on the EORTC Scoring System. *Nephrourol Mon* 2016; 8(1):e33240.
2. Song PH, Cho S, Ko YH. Decision Based on Narrow Band Imaging Cystoscopy without a Referential Normal Standard Rather Increases Unnecessary Biopsy in Detection of Recurrent Bladder Urothelial Carcinoma Early after Intravesical Instillation. *Cancer Res Treat* 2016; 48(1):273-80.
3. Kobatake K, Mita K, Ohara S, et al. Advantage of transurethral resection with narrow band imaging for non-muscle invasive bladder cancer. *Oncol Lett* 2015; 10(2):1097-1102.
4. Ye Z, Hu J, Song X, et al. A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study. *Sci Rep* 2015; 5:10905.
5. Shen YJ, Zhu YP, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a "second look" matters? *Int Urol Nephrol* 2012; 44(2):451-7.
6. Zhu YP, Shen YJ, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of clinically unconfirmed positive urine cytology. *Urol Int* 2012; 88(1):84-7.
7. Tatsugami K, Kuroiwa K, Kamoto T, et al. Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. *J Endourol* 2010; 24(11):1807-11.
8. Cauberg EC, Kloen S, Visser M, et al. Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. *Urology* 2010; 76(3):658-63.
9. Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. *BJU Int* 2008; 102(9):1111-4.
10. Palou J, Hernandez C, Solsona E, et al. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study. *BJU Int* 2015; 116(1):37-43.
11. Lapini A, Minervini A, Masala A, et al. A comparison of hexaminolevulinate (Hexvix((R))) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study. *Surg Endosc* 2012; 26(12):3634-41.
12. Burgues JP, Conde G, Oliva J, et al. [Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group]. *Actas Urol Esp* 2011; 35(8):439-45.
13. Ray ER, Chatterton K, Khan MS, et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. *BJU Int* 2010; 105(6):789-94.
14. Schmidbauer J, Remzi M, Klatter T, et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. *Eur Urol* 2009; 56(6):914-9.
15. Geavlete B, Multescu R, Georgescu D, et al. Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors. *J Endourol* 2009; 23(6):977-81.
16. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. *J Urol* 2007; 178(1):68-73; discussion 73.
17. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. *J Urol* 2003; 170(1):226-9.
18. Grimbergen MCM, van Swol CFP, Jonges TGN, et al. Reduced Specificity of 5-ALA Induced Fluorescence in Photodynamic Diagnosis of Transitional Cell Carcinoma after Previous Intravesical Therapy. *European Urology* 2003; 44(1):51-56.
19. Filbeck T, Pichlmeier U, Knuechel R, et al. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? *Urology* 2002; 60(6):1025-8.

- 1 20. De Dominicis C, Liberti M, Perugia G, et al. Role of 5-aminolevulinic acid in the diagnosis and  
2 treatment of superficial bladder cancer: improvement in diagnostic sensitivity. *Urology* 2001;  
3 57(6):1059-62.
- 4 21. Ehsan A, Sommer F, Haupt G, et al. Significance of fluorescence cystoscopy for diagnosis of superficial  
5 bladder cancer after intravesical instillation of delta aminolevulinic acid. *Urol Int* 2001; 67(4):298-304.
- 6 22. Jeon SS, Kang I, Hong JH, et al. Diagnostic efficacy of fluorescence cystoscopy for detection of  
7 urothelial neoplasms. *J Endourol* 2001; 15(7):753-9.
- 8 23. Zaak D, Kriegmair M, Stepp H, et al. Endoscopic detection of transitional cell carcinoma with 5-  
9 aminolevulinic acid: results of 1012 fluorescence endoscopies. *Urology* 2001; 57(4):690-4.
- 10 24. Filbeck T, Roessler W, Knuechel R, et al. Clinical results of the transurethral resection and evaluation  
11 of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of  
12 5-aminolevulinic acid. *J Endourol* 1999; 13(2):117-21.
- 13 25. Riedl CR, Plas E, Pfluger H. Fluorescence detection of bladder tumors with 5-amino-levulinic acid. *J*  
14 *Endourol* 1999; 13(10):755-9.
- 15 26. D'Hallewin MA, Vanherzeele H, Baert L. Fluorescence detection of flat transitional cell carcinoma after  
16 intravesical instillation of aminolevulinic acid. *Am J Clin Oncol* 1998; 21(3):223-5.
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	Title page
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	None
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5-6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Appendix
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	Figure1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6-7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8





# PRISMA 2009 Checklist

Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	7-8
----------------------	----	---	-----

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6-7
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8-9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Supplementary Figure 6
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Supplementary Table 1
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	9-10
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	10
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10-12
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	12
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	12
<b>FUNDING</b>			



# PRISMA 2009 Checklist

Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	13-14
---------	----	--	-------

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only

# BMJ Open

## Diagnostic Performance of Image Technique-Based Transurethral Resection for Non-muscle Invasive Bladder Cancer: Systematic Review and Diagnostic Meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028173.R2
Article Type:	Original research
Date Submitted by the Author:	20-Sep-2019
Complete List of Authors:	Chen, Changhao; Sun Yat-Sen Memorial Hospital, Department of Urology Huang, Hao; Sun Yat-Sen Memorial Hospital, Department of Urology Zhao, Yue; the First Affiliated Hospital of Sun Yat-Sen University, Department of Gastroenterology Liu, Hao; Chengdu Fifth People's Hospital, Department of Urology Sylvester, Richard; EAU Guidelines Office, Brussels Lin, Tianxin; Sun Yat-Sen Memorial Hospital, Department of Urology Huang, Jian; Sun Yat-Sen Memorial Hospital, Department of Urology
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Diagnostics, Urology
Keywords:	bladder cancer, diagnostic performance, Narrow band imaging, photodynamic diagnosis, white light-guided cystoscopy

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 1 **Diagnostic Performance of Image Technique-Based Transurethral Resection for**  
5  
6 2 **Non-muscle Invasive Bladder Cancer: Systematic Review and Diagnostic Meta-analysis**

7  
8  
9 3 Changhao Chen<sup>1,2#</sup>; Hao Huang<sup>1,2#</sup>; Yue Zhao<sup>3</sup>; Hao Liu<sup>4</sup>; Richard J. Sylvester<sup>5</sup>; Tianxin  
10 4 Lin<sup>1,2\*</sup>; Jian Huang<sup>1,2\*</sup>

11  
12 5 <sup>1</sup>Department of Urology, <sup>2</sup>Guangdong Provincial Key Laboratory of Malignant Tumor  
13 6 Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,  
14 7 Guangdong, P. R. China

15  
16 8 <sup>3</sup> Department of Interventional Oncology, Sun Yat-Sen University First Affiliated Hospital,  
17 9 Guangzhou, China;

18  
19 10 <sup>4</sup>Department of Urology, Chengdu Fifth People's Hospital, Chengdu, P. R. China

20  
21 11 <sup>5</sup>European Association of Urology Guidelines Office, Arnhem, Netherlands

22  
23  
24  
25  
26  
27 13 #These authors contributed equally to this study.

28  
29 14 \*Corresponding authors, to whom requests for reprints should be addressed.

30  
31 15 Jian Huang MD, PhD

32  
33 16 Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107

34  
35 17 Yan-Jiang Xi Road, Guangzhou, 510120, China

36  
37 18 Tel. +86 20 81332603; Fax: +86 20 81332853.

38  
39 19 E-mail address: [cch1988@163.com](mailto:cch1988@163.com)

40  
41 20 Tianxin Lin MD, PhD

42  
43 21 Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107

44  
45 22 Yan-Jiang Xi Road, Guangzhou, 510120, China

46  
47 23 Tel. +86 20 81332603; Fax: +86 20 81332853.

48  
49 24 E-mail address: [tianxinl@sina.com](mailto:tianxinl@sina.com)

50  
51 25

## 1 ABSTRACT

2 **Objective** To explore the diagnostic performance of image technique-based transurethral  
3 resection for bladder cancer, with white light-guided cystoscopy (WLC) as the reference  
4 standard.

5 **Design** Systematic review and meta-analysis.

6 **Data sources** PubMed/MEDLINE, Web of Science, the Cochrane Library, Central Register  
7 of Controlled Trials, and Embase from inception to 31<sup>st</sup> March 2018.

8 **Methods** Included studies reported the diagnostic performance of photodynamic diagnosis  
9 (PDD) with 5-aminolevulinic acid (5-ALA), PDD with hexaminolevulinic acid (HAL), or  
10 narrow band imaging (NBI), with WLC as the reference standard at the patient or lesion  
11 level. The studies' risk of bias (RoB) was assessed using Quality Assessment of Diagnostic  
12 Studies-2 (QUADAS-2). Data were pooled using a random-effect diagnostic meta-analysis  
13 and subgroup analyses were performed.

14 **Results:** Twenty-six studies comprising a total of 3979 patients were included in this  
15 diagnostic meta-analysis. Pooled sensitivity (SSY), specificity (SPY), diagnostic odds ratio  
16 (DOR), and area under the receiver operating characteristic curve (AUROC) values were  
17 calculated per group for NBI, HAL, and 5-ALA at the lesion or patient level. NBI showed  
18 significant diagnostic superiority compared with WLC at the lesion level (SSY 0.94, 95%  
19 confidence interval (CI), 0.82–0.98; SPY 0.79, 95% CI, 0.73–0.85; DOR 40.09, 95% CI,  
20 20.08–80.01; AUROC 0.88, 95% CI, 0.85–0.91). NBI presented the highest DOR (358.71,  
21 95% CI, 44.50–2891.71) in the patient level. Subgroup analyses were performed on studies  
22 with low to moderate RoB and at least 100 patients at the lesion level. These results were

1  
2  
3  
4 1 consistent with those of the overall analysis.  
5

6 2 **Conclusions** Pooled data indicated that image technique-based transurethral resection (NBI,  
7  
8  
9 3 HAL, and 5-ALA) showed diagnostic superiority compared with WLC. Moreover, NBI is  
10  
11 4 potentially the most promising diagnostic intervention, showing the best diagnostic  
12  
13  
14 5 performance outcomes. Further prognostic outcomes of novel imaging technologies  
15  
16  
17 6 compared with those WLC should be explored in addition to current diagnostic performance  
18  
19  
20 7 analysis.  
21

22 8 **Key words:** bladder cancer, diagnostic performance, Narrow band imaging, photodynamic  
23  
24  
25 9 diagnosis, white light-guided cystoscopy  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 **Strengths and limitations of this study**

- 2 ● This is the first systematic review and diagnostic meta-analysis exploring diagnostic  
3 accuracy of image technique based transurethral resection compared with WLC.
- 4 ● Our study includes the stringent methodology used to synthesize the evidence obtained,  
5 such as adhering to PRISMA guidelines, using standardized definitions of diagnostic  
6 performance analysis and applying QUADAS-2 tool for RoB assessment.
- 7 ● Most included studies had a low or moderate risk of bias. All studies clearly reported  
8 methodology for the index test and reference standard, and were not considered a  
9 significant source of potential bias.
- 10 ● The further sensitivity analysis was based on relatively few studies, but we used  
11 random-effect models to compensate for clinical and methodological diversity among  
12 studies.
- 13 ● The lack of data on important clinical variables, such as grade and stage of disease,  
14 primary vs recurrent disease and intravesical instillation settings, may introduce clinical  
15 heterogeneity and prevent further sensitivity analyses. We attempted to minimize biases  
16 by standardizing data extraction and performing several sensitivity analyses.

## 1 INTRODUCTION

2 Bladder cancer is a widespread malignancy with an estimated 80,470 newly diagnosed  
3 cases and 17,670 deaths in USA in 2019, among which about 75% of patients presented with  
4 non-muscle invasive bladder cancer (NMIBC)<sup>1 2</sup>. Currently, white light cystoscopy (WLC) is  
5 the gold-standard technique to detect bladder cancer, despite having an unsatisfactory  
6 accuracy to detect disease. The detection reliability for smaller tumors or carcinoma *in situ*  
7 (CIS) is poor, leading to markedly high recurrence, with up to 30% of patients having a tumor  
8 identified at the first-check cystoscopy at 3 months and 50% of patients developing tumors  
9 within 12 months<sup>3 4</sup>. Thus, different optical imaging techniques have emerged as an adjunct  
10 to WLC to improve the visualization of tumors via contrast enhancement.

11 Photodynamic diagnosis (PDD) is performed using blue-violet (380–440 nm) light with  
12 intravesical instillation of 5-aminolevulinic acid (5-ALA) or hexaminolevulinic acid (HAL).  
13 The effect of 5-ALA-induced fluorescence on tumor detection in the urinary bladder has  
14 identified it as an efficient method to map the entire mucosa to detect urothelial tumors and  
15 flat CIS lesions<sup>5-7</sup>. HAL, the lipophilic hexylester of 5-ALA, has been commercially available  
16 since 2006, and has been established as the preferred intravesical agent to detect NMIBC.  
17 However, intravesical inflammation leads to decreased specificity and pre-operative  
18 procedures are technically complex and costly.

19 Narrow band imaging (NBI) is a new image-processing modality that filters white light  
20 down to two narrow band widths of 415 and 540 nm, with advantage of avoiding the need for  
21 intravesical contrast administration<sup>8</sup>. Hemoglobin absorbs these wavelengths preferentially,  
22 resulting in dark neovascularized bladder cancer appearing very different from the light



1 background of the normal mucosa. The superior diagnostic performance of NBI compared  
2 with WLC has been confirmed in several studies<sup>9-11</sup>. Overall, NBI led to a 9.9% increase in  
3 the detection rate at the patient level and a 19.2% increase in lesion detection in a recent  
4 meta-analysis, while subgroup analysis showed that NBI was associated with a 53%  
5 reduction in the recurrence rate at 3 months and 19% at 12 months compared with those of  
6 WLC<sup>12</sup>. Noticeably, NBI might be associated with increased false-positives, especially for  
7 patients with prior intravesical instillations<sup>13</sup>.

8 As a standard procedure, cystoscopy is performed using white light. However, the use of  
9 white light can lead to lesions that are present but not visible being missed. New imaging  
10 techniques could improve cancer detection compared with WLC; however, some studies  
11 showed that new imaging techniques might produce higher false positive rates than WLC<sup>13-15</sup>.  
12 In addition, their complex procedures and costs restrict their wider application<sup>16</sup>. Therefore, it  
13 is still uncertain which technique could better improve the diagnostic accuracy of bladder  
14 cancer detection. The present study aimed to perform a systematic review and meta-analysis  
15 to assess the diagnostic performance of PDD using 5-ALA, PDD using HAL, and NBI  
16 against the current reference standard of WLC for NMIBC.

## 1       2       3 4       1    **METHODS**

5  
6       2       The diagnostic meta-analysis was conducted based on the Meta-analysis of Observational  
7  
8  
9       3       Studies in Epidemiology statement<sup>17</sup>. All included studies were observational studies. When  
10  
11  
12      4       an included primary study did not match the Standards for Reporting of Diagnostic Accuracy  
13  
14      5       statement, we gathered the information by contacting the authors<sup>18</sup>.

### 16      6       **Literature search**

17  
18  
19      7       Studies reporting the diagnostic performance of PDD with 5-ALA, PDD with HAL, or  
20  
21  
22      8       NBI, with WLC as reference standard, were retrieved from multiple databases including  
23  
24  
25      9       PubMed/MEDLINE, Web of Science, the Cochrane Library, Central Register of Controlled  
26  
27  
28     10      Trials and Embase up to 31<sup>st</sup> March 2018. The following MeSH free and combined terms,  
29  
30     11      which were adjusted for the different databases terms, were used: “photodynamic diagnosis,  
31  
32     12      PDD, hexaminolevulinate, HAL, 5-aminolevulinate acid, 5-ALA, narrow imaging, NBI,  
33  
34     13      white light cystoscopy, urothelial cell carcinoma of bladder, transitional cell carcinoma,  
35  
36     14      bladder cancer, bladder tumor, and BCa”. The full search strategy is shown in the Appendix  
37  
38  
39     15      (supplementary material). The review was performed according to Preferred Reporting Items  
40  
41  
42     16      for Systematic Reviews (PRISMA)<sup>19</sup> and Standards for Reporting Diagnostic Accuracy  
43  
44  
45     17      Studies (STARD)<sup>20</sup>. The search was restricted to English-language publications. At least two  
46  
47  
48     18      reviewers (CHC and HH) screened all the abstracts and full-text articles independently.  
49  
50  
51     19      Disagreement was resolved by consultation with an independent arbiter (JH).

### 52     20      **Inclusion and exclusion criteria**

53  
54  
55     21      The inclusion criteria were as follows: 1) Population: Patients diagnosed with primary  
56  
57  
58     22      NMIBC, or patients previously diagnosed with NMIBC (recurrent tumors); 2) Reference  
59  
60

1 standard: WLC must be provided as the reference standard for all patients, and the diagnosis  
2 of NMIBC was confirmed by histopathological examination; 3) studies reported data of  
3 intra-patient comparison; 4) when two or more studies provided data from the same  
4 institution during an overlapping time period, only the updated data was included in this  
5 study.

6 Articles were excluded if the full-text article was not written in English. Abstracts,  
7 conference articles, historical overviews, case studies, reviews, and meta-analyses were not  
8 considered. Studies that failed to report on sensitivity and specificity data or both in  
9 comparison with WLC were excluded. For missing or unclear data, we contacted the authors  
10 to obtain more information.

### 11 **Patient and Public Involvement**

12 Patients and the public were not involved in this research.

### 13 **Study Quality**

14 The Quality Assessment of Diagnostic Studies-2 (QUADAS-2)<sup>21</sup> and the Strength Of  
15 Recommendation Taxonomy (SORT) numerical scale were applied to the included studies<sup>22</sup>.  
16 Both checklists were performed independently by two authors (YZ and CHC); disagreement  
17 was resolved by consultation with an independent arbiter (JH). The “low risk of bias (RoB)”  
18 was defined as at least three domains with “low” in both categories and without any domains  
19 evaluated as “high” in either category; “moderate RoB” was defined as at least two domains  
20 with “low” in both categories and without any domain scoring “high” in either category; in  
21 addition to this was defined as “high” RoB.

### 22 **Data Extraction**

1  
2  
3  
4 1 The following data were extracted from the selected studies: 1) Study characteristics (first  
5  
6  
7 2 author, study design, number of patients, and follow-up); 2) intervention characteristics  
8  
9 3 (index tests, duration of follow-up, schedule, and nature of WLC); 3) patient characteristics  
10  
11 4 (age, sex, NMIBC patients, and tumor lesions); 4) diagnostic performance measures  
12  
13  
14 5 (sensitivity (SSY), specificity (SPY), negative predictive value (NPV), positive predictive  
15  
16  
17 6 value (PPV), false positive rate (FPR), and false negative rate (FNR)). Data were extracted  
18  
19  
20 7 from each study at the lesion or patient level to assess 5-ALA, HAL, and NBI as the index  
21  
22 8 test using WLC as the reference standard, with positive or negative disease being determined  
23  
24  
25 9 using histopathological examination.

26  
27  
28 10 The primary outcomes of SSY, SPY, NPV, PPV, FPR, and FNR for individual studies  
29  
30 11 were calculated using the following standard definitions. SSY was defined as the proportion  
31  
32 12 of positive patients or lesions with index tests in all cases of WLC-positive findings. SPY  
33  
34  
35 13 was defined as the proportion of negative patients or lesions with index tests in all cases of  
36  
37  
38 14 WLC-negative findings. NPV was defined as the proportion of true negatives findings (both  
39  
40  
41 15 negative in index tests and WLC) in all index test-negative cases or lesions. PPV was  
42  
43  
44 16 defined as the proportion of true positives findings (both positive in index tests and WLC) in  
45  
46  
47 17 all index test-positive cases or lesions. FNR was defined as the proportion of index  
48  
49  
50 18 test-negative findings in all cases of WLC-positive cases or lesions. FPR was defined as the  
51  
52  
53 19 proportion of index test-positive findings in all cases of WLC-negative cases or lesions.

## 20 **Statistical analysis**

21 Separate meta-analyses were performed for the currently new technology-assisted  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
cystoscopy in patients with NMIBC to best summarize the totality of the available evidence.

1  
2  
3  
4 1 The diagnostic meta-analysis was performed using Stata 13.0 (StataCorp, College Station,  
5  
6 2 TX, USA) with the metan and midas commands. A two-sided p value of less than 0.05 was  
7  
8  
9 3 considered significant. In this study, a random-effect model was applied to quantify the  
10  
11 4 pooled sensitivity, specificity, diagnostic odds ratio (DOR), and area under the receiver  
12  
13 5 operating characteristic curve (AUROC), with 95% confidence intervals (CIs) of the  
14  
15 6 compared end points. DOR reflects the diagnostic performance of a new imaging technique  
16  
17 7 to detect lesions. A DOR value of 1 indicates that the test has no discriminative power; the  
18  
19 8 higher the DOR value, the better the diagnostic performance of the new imaging technique.  
20  
21  
22 9 The AUROC is an overall summary measure index of the diagnostic accuracy. A perfect test  
23  
24 10 will have an AUROC close to 1 and a poor test will have an AUROC close to 0.5<sup>23</sup>. We will  
25  
26 11 plot the sensitivities and specificities in the Summary Receiver Operating Curve (SROC)  
27  
28 12 space, using different symbols for different imaging techniques, and used RevMan 5.2  
29  
30 13 software to build hierarchical SROC curves for each imaging technique. We also formulated  
31  
32 14 forest plots of the summary measures of accuracy and examined the heterogeneity of the  
33  
34 15 summary measures of sensitivity and specificity. The publication bias was assessed using  
35  
36 16 Deeks' funnel plot, and statistical significance was determined using Deeks' asymmetry  
37  
38 17 test<sup>24 25</sup>. To explore the effect of heterogeneity on the results, subgroup analyses were  
39  
40 18 planned based on disease grade (low grade vs. high grade), stage (pTa vs. pT1), setting  
41  
42 19 (primary vs. recurrent tumors), number of participants (studies with n >100 patients only),  
43  
44 20 and on studies with low to moderate RoB.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1           2           3 4           1   **RESULTS**

### 5 6           2   **Search and Study Selection**

7  
8           3       The flow diagram summarizing the literature screening and inclusion process is presented  
9  
10           4       in Figure 1. Of the 652 potentially relevant articles identified in the database search, 271  
11  
12           5       studies were excluded as duplicates. We excluded 278 studies when screening the titles and  
13  
14           6       abstracts: 32 were editorials or letters, 24 were reviews or meeting abstracts, 85 were  
15  
16           7       non-comparative studies, and 137 papers concerned an obviously different topic. During the  
17  
18           8       screening of 103 full-text articles, 36 studies were excluded for not being relevant to this  
19  
20           9       review and another 41 studies were excluded for not having within-patient comparisons.  
21  
22           10       Finally, 26 studies<sup>11 15 26-49</sup> were included in the diagnostic meta-analysis.  
23  
24  
25  
26  
27  
28  
29

### 30           11   **Study Demographics**

31  
32           12       The characteristics of the 26 studies included in this meta-analysis are summarized in  
33  
34           13       Table 1. The studies were published from 1994 to 2016 with sample sizes ranging from 12 to  
35  
36           14       605 patients. The mean or median age and male/female ratio showed no significant  
37  
38           15       differences among included studies. In nine studies, the NBI diagnostic intervention was  
39  
40           16       applied, while 5-ALA-based PDD was conducted in nine studies, and HAL-based PDD in  
41  
42           17       eight studies. Most of the enrolled patients in the included studies suffered from NMIBC.  
43  
44  
45  
46  
47

### 48           18   **Lesion level analysis**

49  
50           19       All studies used non-standardized definitions to calculate their diagnostic outcomes, in  
51  
52           20       which case the results of the included studies were recalculated using standard definitions  
53  
54           21       from the raw data provided (Supplementary Table 1). The diagnostic meta-analysis results  
55  
56           22       are presented using lesion-level and patient-level analyses. Based on the lesion level, the  
57  
58  
59  
60

1 Forest plot of estimates of the DOR for NBI, HAL, and 5-ALA compared with WLC are  
2 shown in Figure 2. The pooled DOR values for NBI, HAL, and 5-ALA were 40.09 (95% CI,  
3 20.08–80.01, Figure 2A), 78.14 (95% CI, 31.42–194.28, Figure 2B), and 18.14 (95% CI,  
4 4.28–76.87, Figure 2C), respectively. The SROC curves for NBI, HAL, and 5-ALA are  
5 shown in Figure 3A. The AUROC values of NBI, HAL, and 5-ALA were 0.88 (95% CI,  
6 0.85–0.91), 0.94 (95% CI, 0.92–0.96), and 0.82 (95% CI, 0.79–0.85), respectively.  
7 Importantly, the results of the SSY and SPY for each intervention are shown in  
8 Supplementary Figures 1–3. The pooled estimates for the SSY data for NBI, HAL, and  
9 5-ALA were 0.94 (95% CI, 0.82–0.98, Supplementary Figure 1A), 0.95 (95% CI, 0.91–0.98,  
10 Supplementary Figure 2A), and 0.90 (95% CI, 0.71–0.97, Supplementary Figure 3A),  
11 respectively, whereas the SPY values for NBI, HAL, and 5-ALA were 0.79 (95% CI,  
12 0.73–0.85, Supplementary Figure 1B), 0.81 (95% CI, 0.74–0.87, Supplementary Figure 2B),  
13 and 0.69 (95% CI, 0.57–0.79, Supplementary Figure 3B), respectively, presenting superiority  
14 compared with WLC. The DOR and AUROC values of NBI, HAL, and 5-ALA indicated  
15 excellent diagnostic performance.

### 16 Patient level analysis

17 For the patient level analysis, the AUROC, SSY, and SPY could not be calculated because  
18 few studies included these data. Figure 2 shows the Forest plots of DOR for NBI, HAL, and  
19 5-ALA. NBI showed the highest DOR. The DOR values for NBI and HAL were 358.71 (95%  
20 CI, 44.50–2891.71, Figure 2D) and 59.95 (95% CI, 24.30–147.92, Figure 2E), respectively,  
21 presenting a better performance compared with that of WLC. The SROC curves for NBI,  
22 HAL, and 5-ALA are shown in Figure 3B. However, the DOR value for 5-ALA was 79.52

1  
2  
3  
4 1 (95% CI, 0.94–6759.92, Figure 2F), and did not show a statistical difference.  
5  
6

## 7 2 **Subgroup Analysis**

8  
9 3 Subgroup analyses were performed on studies with low to moderate RoB and at least 100  
10  
11 4 patients at the lesion level. The diagnostic performance results for studies with low to  
12  
13 5 moderate RoB and at least 100 patients are shown in Supplementary Table 2. The Forest plot  
14  
15 6 of the estimates of the pooled DOR for NBI, HAL, and 5-ALA with low to moderate RoB are  
16  
17 7 shown in Supplementary Figure 4; while the Forest plot of the estimates of the pooled DOR  
18  
19 8 for NBI, HAL, and 5-ALA with at least 100 patients are shown in Supplementary Figure 5.  
20  
21 9 These results were consistent with those obtained in the overall analysis.  
22  
23  
24  
25

## 26 10 **RoB of the included studies**

27  
28  
29 11 The comparison-adjusted funnel plots of the diagnostic meta-analysis were not suggestive  
30  
31 12 of any publication bias, as shown in Figure 4. The QUADAS-2 tool was applied for RoB  
32  
33 13 assessment of the included studies in our meta-analysis (Supplementary Figure 6). Overall,  
34  
35 14 all studies reported methodology for the index test and reference standard clearly, without a  
36  
37 15 significant source of potential bias. Among them 69% (18/26) of the studies were presented  
38  
39 16 as low or unclear RoB across most domains. The risk of bias in the patient selection in three  
40  
41 17 studies was deemed high because of the absence of the consecutive inclusion of patients; four  
42  
43 18 studies were deemed to have a high RoB for flow and timing.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## 1 DISCUSSION

2 Our systematic review indicated that the pooled diagnostic performance of NBI, HAL, or  
3 5-ALA showed excellent efficacy compared with WLC. NBI could potentially be the most  
4 promising diagnostic intervention for patients with NMIBC, with advantages in terms of  
5 simplicity, cost, and reliability. In the present study, we have summarized the diagnostic  
6 performance of new technique-assisted cystoscopy strategies for NMIBC. A diagnostic  
7 meta-analysis was further undertaken to estimate the diagnostic performance of NBI, HAL,  
8 and 5-ALA compared with that of WLC. WLC has been the standard method to detect  
9 urothelial cell carcinoma of the bladder. However, the sensitivity of WLC is unsatisfactory  
10 and it can miss small ‘satellite’ tumors or carcinoma *in situ*. Thus, new imaging techniques  
11 (photodynamic diagnosis, narrow band imaging) have been introduced to enhance bladder  
12 cancer visualization to improve diagnostic accuracy and the thoroughness of resection.  
13 Several studies have demonstrated that the new imaging techniques showed superior  
14 diagnostic performance compared with WLC<sup>11 50</sup>. However, the application of these new  
15 imaging techniques has been limited by their increased false positives caused by intravesical  
16 instillation or inflammation, their technical complexity and increased cost<sup>13-16</sup>. It remains  
17 uncertain which technique could better improve the diagnostic accuracy of bladder cancer  
18 detection beyond the standard WLC. Virtually all the techniques assessed in this review  
19 were based on the reference standard of WLC, and new technique-assisted cystoscopy  
20 showed diagnostic superiority compared with conventional WLC. In this context, adoption  
21 of these strategies for practical bladder cancer diagnosis is essential. The results of the  
22 present study strongly suggested that new imaging-based technologies, in particular NBI,

1  
2  
3  
4 1 would be promising diagnostic interventions for bladder cancer detection in clinical  
5  
6 2 practice.

7  
8  
9 3 In response to the latent disadvantages of WLC, PDD, and NBI have been developed  
10  
11 4 recently to improve the visualization of bladder tumors. The diagnostic superiority of PDD  
12  
13 5 or NBI over WLC for tumor detection has been demonstrated in several studies<sup>11 51 52</sup>. A  
14  
15 6 meta-analysis comparing PDD with WLC found a 21% increase in tumor detection with  
16  
17 7 PDD in the pooled estimates for both patients and biopsies<sup>53</sup>. NBI, another optical  
18  
19 8 enhancement technology, improves diagnostic accuracy by increasing the contrast of the  
20  
21 9 superficial vasculature between the normal mucosa and tumor tissue. Previous studies  
22  
23 10 reported significant improvement in the detection of bladder tumors using NBI cystoscopy  
24  
25 11 compared with standard WLC<sup>11 13</sup>. Our previous meta-analysis indicated that NBI identifies  
26  
27 12 an additional 17% of patients and an additional 24% of tumors compared with WLC<sup>54</sup>.  
28  
29 13 However, these studies did not use standardized diagnostic accuracy definitions. Our  
30  
31 14 diagnostic meta-analysis applied standard diagnostic accuracy definitions and furthermore,  
32  
33 15 the pooled estimates demonstrated that new technique assisted-cystoscopy had significant  
34  
35 16 diagnostic superiority compared with conventional WLC, demonstrating the sub-optimal  
36  
37 17 performance of WLC in diagnosing NMIBC.

38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48 18 A study performed by Burger<sup>55</sup> showed that HAL assisted transurethral resection (TUR)  
49  
50 19 significantly reduced the recurrence rate at 9-12 months compared with WLC-assisted TUR  
51  
52 20 alone. In addition, Lee et al. performed a meta-analysis<sup>56</sup> evaluating oncological outcomes  
53  
54 21 for WLC, PDD, and NBI-assisted TUR, which showed that both PDD and NBI reduced the  
55  
56 22 recurrence rate compared with WLC. However, the therapeutic effectiveness of new  
57  
58  
59  
60

1  
2  
3  
4 1 technique-assisted TUR, in terms of recurrence and progression, could not be demonstrated  
5  
6 2 in the present review. Further therapeutic efficacy analysis is needed to identify promising  
7  
8  
9 3 interventions.

10  
11 4 The strengths of our study include the stringent methodology used for searching and the  
12  
13 5 study inclusion procedure, the standard definition of diagnostic performance and data  
14  
15 6 extraction, the use of the strict diagnostic meta-analysis, and the specific QUADAS-2 tool  
16  
17 7 for RoB assessment. Moreover, the strict diagnostic meta-analysis and further subgroup  
18  
19 8 analysis was applied to synthesize the diagnostic accuracy to obtain a reliable result.  
20  
21  
22 9 However, potential study limitations should be acknowledged. The lack of data on important  
23  
24 10 clinical variables, such as grade and stage of disease, primary vs. recurrent disease, and  
25  
26 11 intravesical instillation settings, might have introduced clinical heterogeneity and prevented  
27  
28 12 further subgroup analyses. The predictive performance of recurrence or progression was not  
29  
30 13 demonstrated in our study, which might decrease the reliability of diagnostic performance.  
31  
32 14 We have attempted to minimize bias throughout the whole procedure, with rigorous search  
33  
34 15 and selection criteria, standard data extraction, and re-calculation, and subgroup analysis  
35  
36 16 application, to evaluate the robustness of our findings.

37  
38 17 In summary, this meta-analysis provided pooled diagnostic accuracy for NBI, HAL, and  
39  
40 18 5-ALA techniques for patients with NMIBC in comparison with WLC as the reference  
41  
42 19 standard. The results demonstrated that the diagnostic performances of NBI, HAL, and  
43  
44 20 5-ALA were superior to that of WLC at the lesion level in diagnostic meta-analysis. The  
45  
46 21 findings demonstrate the superior diagnostic performance of new imaging techniques in  
47  
48 22 bladder detection compared with conventional WLC. These new imaging techniques are  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 1 promising diagnostic interventions to improve clinical procedures in bladder cancer

5  
6 2 detection.

7  
8  
9 3

#### 10 4 **Abbreviations**

11  
12  
13  
14 5 CI: Confidence intervals; CIS: carcinoma in situ; DOR: Diagnostic odds ratios; DTA:

15  
16  
17 6 Diagnostic test accuracy; FNR: False negative rate; FPR: False positive rate; IQR:

18  
19  
20 7 Interquartile range; HAL: hexylaminolevulinate; NBI: and narrow band imaging; NMIBC:

21  
22 8 Non-muscle-invasive bladder cancer; NPV: Negative predictive value; PDD: Photodynamic

23  
24  
25 9 diagnosis; PPV: Positive predictive value; SPY: Specificity; SSY: Sensitivity; SROC:

26  
27 10 Summary receiver operating curve; AUROC: Area under the receiver operating characteristic

28  
29  
30 11 curve; TURBT: Transurethral resection of bladder tumors; WLC: White light cystoscopy;

31  
32  
33 12 5-ALA: 5-aminolaevulinic acid.

34  
35  
36  
37 13

#### 38 14 **Acknowledgements**

39  
40 15 We would like to thank Prof. J.X. Zhang, Department of Medical Statistics and

41  
42 16 Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, China, for

43  
44  
45 17 statistical advice and research comments.

46  
47  
48  
49 18

#### 50 51 19 **Contributors**

52  
53  
54 20 CHC conceptualized and designed the study, drafted the initial and final manuscript, provided

55  
56 21 funding support. HH contributed to data collection and extraction, data analysis and

57  
58  
59 22 interpretation, drafted initial and final manuscript. YZ contributed to article screening, data

1 collection and extraction, assessment of risk of bias and drafting manuscript: HL contributed  
2 to article screening, data collection and extraction and assessment of risk of bias. RJ Sylvester  
3 led and supervised statistical analysis, provided administrative support. TXL and JH  
4 contributed to study conceptualization and design, supervised study implementation, and  
5 critically reviewed the manuscript.  
6

### 7 **Funding**

8 This study was funded by the National Natural Science Foundation of China (Grant  
9 No. 81572514,81472384, 81472381, 81402106, 81772719, 81772728, 91740119, 91529301);  
10 Guangdong Medical Research Fund (A2018330); Science and Technology Program of  
11 Guangzhou (Grant No. 201604020156, 201604020177, 201707010116, 201803010098);  
12 National Natural Science Foundation of Guangdong (Grant No. 2018A030313564,  
13 2018B030311009, 2018A030310250,2016A030313321, 2015A030311011,  
14 2015A030310122). Yixian Youth project of Sun Yat-sen Memorial Hospital  
15 (YXQH201812).

### 17 **Competing interests**

18 None declared.

### 20 **Patient consent**

21 Not required.

## 1 Provenance and peer review

2 Not commissioned; externally peer reviewed.

## 3 Data sharing statement

4 There are no additional data available.

## 7 References

- 8 1. Antoni S, Ferlay J, Soerjomataram I, et al. Bladder Cancer Incidence and Mortality: A Global  
9 Overview and Recent Trends. *Eur Urol* 2016 doi: 10.1016/j.eururo.2016.06.010
- 10 2. Chen C, He W, Huang J, et al. LNMAT1 promotes lymphatic metastasis of bladder cancer via  
11 CCL2 dependent macrophage recruitment. *Nat Commun* 2018;9(1):3826. doi:  
12 10.1038/s41467-018-06152-x [published Online First: 2018/09/22]
- 13 3. Schwaibold HE, Sivalingam S, May F, et al. The value of a second transurethral resection for T1  
14 bladder cancer. *BJU Int* 2006;97(6):1199-201. doi: 10.1111/j.1464-410X.2006.06144.x
- 15 4. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in  
16 individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined  
17 analysis of 2596 patients from seven EORTC trials. *Eur Urol* 2006;49(3):466-5; discussion  
18 75-7. doi: 10.1016/j.eururo.2005.12.031
- 19 5. Grimbergen MCM, van Swol CFP, Jonges TGN, et al. Reduced Specificity of 5-ALA Induced  
20 Fluorescence in Photodynamic Diagnosis of Transitional Cell Carcinoma after Previous  
21 Intravesical Therapy. *European Urology* 2003;44(1):51-56. doi:  
22 10.1016/s0302-2838(03)00210-0

- 1  
2  
3  
4 1 6. Daniltchenko DI, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid  
5  
6 2 fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a  
7  
8 3 prospective randomized study. *The Journal of urology* 2005;174(6):2129-33, discussion 33.  
9  
10 4 doi: 10.1097/01.ju.0000181814.73466.14  
11  
12  
13  
14 5 7. Kriegmair M, Baumgartner R, Knuchel R, et al. Detection of early bladder cancer by  
15  
16 6 5-aminolevulinic acid induced porphyrin fluorescence. *The Journal of urology*  
17  
18 7 1996;155(1):105-9; discussion 09-10. [published Online First: 1996/01/01]  
19  
20  
21  
22 8 8. Bryan RT, Shah ZH, Collins SI, et al. Narrow-band imaging flexible cystoscopy: a new user's  
23  
24 9 experience. *J Endourol* 2010;24(8):1339-43. doi: 10.1089/end.2009.0598 [published Online  
25  
26 10 First: 2010/07/16]  
27  
28  
29  
30 11 9. Naito S, Algaba F, Babjuk M, et al. The Clinical Research Office of the Endourological Society  
31  
32 12 (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral  
33  
34 13 Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted  
35  
36 14 TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year  
37  
38 15 Results. *Eur Urol* 2016 doi: 10.1016/j.eururo.2016.03.053  
39  
40  
41  
42  
43 16 10. Naselli A, Introini C, Timossi L, et al. A randomized prospective trial to assess the impact of  
44  
45 17 transurethral resection in narrow band imaging modality on non-muscle-invasive bladder  
46  
47 18 cancer recurrence. *Eur Urol* 2012;61(5):908-13. doi: 10.1016/j.eururo.2012.01.018  
48  
49  
50  
51 19 11. Ye Z, Hu J, Song X, et al. A comparison of NBI and WLI cystoscopy in detecting  
52  
53 20 non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study. *Sci*  
54  
55 21 *Rep* 2015;5:10905. doi: 10.1038/srep10905 [published Online First: 2015/06/06]  
56  
57  
58  
59 22 12. Xiong Y, Li J, Ma S, et al. A meta-analysis of narrow band imaging for the diagnosis and  
60

- 1  
2  
3  
4 1 therapeutic outcome of non-muscle invasive bladder cancer. *PLoS One*  
5  
6 2 2017;12(2):e0170819. doi: 10.1371/journal.pone.0170819 [published Online First:  
7  
8  
9 3 2017/02/14]
- 10  
11 4 13. Geavlete B, Multescu R, Georgescu D, et al. Narrow band imaging cystoscopy and bipolar plasma  
12  
13  
14 5 vaporization for large nonmuscle-invasive bladder tumors--results of a prospective,  
15  
16  
17 6 randomized comparison to the standard approach. *Urology* 2012;79(4):846-51. doi:  
18  
19  
20 7 10.1016/j.urology.2011.08.081 [published Online First: 2012/02/22]
- 21  
22 8 14. Draga RO, Grimbergen MC, Kok ET, et al. Photodynamic diagnosis (5-aminolevulinic acid) of  
23  
24  
25 9 transitional cell carcinoma after bacillus Calmette-Guerin immunotherapy and mitomycin C  
26  
27  
28 10 intravesical therapy. *Eur Urol* 2010;57(4):655-60. doi: 10.1016/j.eururo.2009.09.037  
29  
30 11 [published Online First: 2009/10/13]
- 31  
32  
33 12 15. Ray ER, Chatterton K, Khan MS, et al. Hexylaminolaevulinate fluorescence cystoscopy in patients  
34  
35  
36 13 previously treated with intravesical bacille Calmette-Guerin. *BJU Int* 2010;105(6):789-94. doi:  
37  
38 14 10.1111/j.1464-410X.2009.08839.x [published Online First: 2009/10/17]
- 39  
40  
41 15 16. Daneshmand S, Schuckman AK, Bochner BH, et al. Hexaminolevulinate blue-light cystoscopy in  
42  
43  
44 16 non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement  
45  
46  
47 17 on appropriate use in the USA. *Nat Rev Urol* 2014;11(10):589-96. doi:  
48  
49 18 10.1038/nrurol.2014.245 [published Online First: 2014/09/24]
- 50  
51 19 17. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a  
52  
53  
54 20 proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE)  
55  
56 21 group. *JAMA* 2000;283(15):2008-12.
- 57  
58  
59 22 18. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of  
60



- 1 diagnostic accuracy: the STARD initiative. *BMJ* 2003;326(7379):41-4.
- 2
- 3
- 4 19. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and  
5  
6 meta-analyses: the PRISMA statement. *Int J Surg* 2010;8(5):336-41. doi:  
7  
8 10.1016/j.ijisu.2010.02.007 [published Online First: 2010/02/23]  
9  
10
- 11 20. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for  
12  
13 reporting diagnostic accuracy studies. *BMJ* 2015;351:h5527. doi: 10.1136/bmj.h5527  
14  
15 [published Online First: 2015/10/30]  
16  
17
- 18 21. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality  
19  
20 assessment of diagnostic accuracy studies. *Annals of internal medicine* 2011;155(8):529-36.  
21  
22 doi: 10.7326/0003-4819-155-8-201110180-00009 [published Online First: 2011/10/19]  
23  
24
- 25 22. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a  
26  
27 patient-centered approach to grading evidence in the medical literature. *Am Fam Physician*  
28  
29 2004;69(3):548-56.  
30  
31
- 32 23. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic  
33  
34 (ROC) curve. *Radiology* 1982;143(1):29-36. doi: 10.1148/radiology.143.1.7063747 [published  
35  
36 Online First: 1982/04/01]  
37  
38
- 39 24. Song F, Khan KS, Dinnes J, et al. Asymmetric funnel plots and publication bias in meta-analyses  
40  
41 of diagnostic accuracy. *Int J Epidemiol* 2002;31(1):88-95. [published Online First: 2002/03/27]  
42  
43
- 44 25. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size  
45  
46 effects in systematic reviews of diagnostic test accuracy was assessed. *J Clin Epidemiol*  
47  
48 2005;58(9):882-93. doi: 10.1016/j.jclinepi.2005.01.016 [published Online First: 2005/08/09]  
49  
50
- 51 26. Zhu YP, Shen YJ, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 clinically unconfirmed positive urine cytology. *Urol Int* 2012;88(1):84-7. doi:  
5  
6 2 10.1159/000333119  
7  
8  
9 3 27. Zaak D, Kriegmair M, Stepp H, et al. Endoscopic detection of transitional cell carcinoma with  
10  
11 4 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. *Urology* 2001;57(4):690-4.  
12  
13  
14 5 [published Online First: 2001/04/18]  
15  
16  
17 6 28. Tatsugami K, Kuroiwa K, Kamoto T, et al. Evaluation of narrow-band imaging as a complementary  
18  
19 7 method for the detection of bladder cancer. *J Endourol* 2010;24(11):1807-11. doi:  
20  
21 8 10.1089/end.2010.0055 [published Online First: 2010/08/17]  
22  
23  
24  
25 9 29. Song PH, Cho S, Ko YH. Decision Based on Narrow Band Imaging Cystoscopy without a  
26  
27 10 Referential Normal Standard Rather Increases Unnecessary Biopsy in Detection of Recurrent  
28  
29 11 Bladder Urothelial Carcinoma Early after Intravesical Instillation. *Cancer Res Treat*  
30  
31 12 2016;48(1):273-80. doi: 10.4143/crt.2014.190  
32  
33  
34  
35 13 30. Shen YJ, Zhu YP, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of  
36  
37 14 primary non-muscle invasive bladder cancer: a "second look" matters? *Int Urol Nephrol*  
38  
39 15 2012;44(2):451-7. doi: 10.1007/s11255-011-0036-5  
40  
41  
42  
43 16 31. Shadpour P, Emami M, Haghdani S. A Comparison of the Progression and Recurrence Risk  
44  
45 17 Index in Non-Muscle-Invasive Bladder Tumors Detected by Narrow-Band Imaging Versus  
46  
47 18 White Light Cystoscopy, Based on the EORTC Scoring System. *Nephrourol Mon*  
48  
49 19 2016;8(1):e33240. doi: 10.5812/numonthly.33240  
50  
51  
52  
53 20 32. Schmidbauer J, Remzi M, Klatter T, et al. Fluorescence cystoscopy with high-resolution optical  
54  
55 21 coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis  
56  
57 22 of urothelial carcinoma of the bladder. *Eur Urol* 2009;56(6):914-9. doi:  
58  
59  
60

- 1  
2  
3  
4 1 10.1016/j.eururo.2009.07.042  
5  
6  
7 2 33. Riedl CR, Plas E, Pfluger H. Fluorescence detection of bladder tumors with 5-amino-levulinic acid.  
8  
9 3 *J Endourol* 1999;13(10):755-9. doi: 10.1089/end.1999.13.755 [published Online First:  
10  
11 4 2000/01/26]  
12  
13  
14 5 34. Palou J, Hernandez C, Solsona E, et al. Effectiveness of hexaminolevulinate fluorescence  
15  
16 6 cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a  
17  
18 7 Spanish multicentre observational study. *BJU Int* 2015;116(1):37-43. doi: 10.1111/bju.13020  
19  
20  
21  
22 8 35. Lapini A, Minervini A, Masala A, et al. A comparison of hexaminolevulinate (Hexvix((R)))  
23  
24 9 fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of  
25  
26 10 the HeRo observational study. *Surg Endosc* 2012;26(12):3634-41. doi:  
27  
28 11 10.1007/s00464-012-2387-0  
29  
30  
31  
32 12 36. Kobatake K, Mita K, Ohara S, et al. Advantage of transurethral resection with narrow band  
33  
34 13 imaging for non-muscle invasive bladder cancer. *Oncol Lett* 2015;10(2):1097-102. doi:  
35  
36 14 10.3892/ol.2015.3280  
37  
38  
39  
40 15 37. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new  
41  
42 16 diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. *The*  
43  
44 17 *Journal of urology* 2003;170(1):226-9. doi: 10.1097/01.ju.0000060782.52358.04  
45  
46  
47  
48 18 38. Jeon SS, Kang I, Hong JH, et al. Diagnostic efficacy of fluorescence cystoscopy for detection of  
49  
50 19 urothelial neoplasms. *J Endourol* 2001;15(7):753-9. doi: 10.1089/08927790152596370  
51  
52 20 [published Online First: 2001/11/08]  
53  
54  
55  
56 21 39. Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging  
57  
58 22 cystoscopy to detect bladder tumour recurrences. *BJU Int* 2008;102(9):1111-4. doi:  
59  
60

- 1  
2  
3  
4 1 10.1111/j.1464-410X.2008.07846.x  
5  
6 2 40. Grimbergen MC, van Swol CF, Jonges TG, et al. Reduced specificity of 5-ALA induced  
7  
8  
9 3 fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous  
10  
11 4 intravesical therapy. *Eur Urol* 2003;44(1):51-6. [published Online First: 2003/06/20]  
12  
13  
14 5 41. Geavlete B, Multescu R, Georgescu D, et al. Hexaminolevulinate fluorescence cystoscopy and  
15  
16 6 transurethral resection of the bladder in noninvasive bladder tumors. *J Endourol*  
17  
18 7 2009;23(6):977-81. doi: 10.1089/end.2008.0574 [published Online First: 2009/05/29]  
19  
20  
21  
22 8 42. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence  
23  
24 9 cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with  
25  
26 10 bladder cancer: a phase III, multicenter study. *The Journal of urology* 2007;178(1):68-73;  
27  
28 11 discussion 73. doi: 10.1016/j.juro.2007.03.028  
29  
30  
31  
32 12 43. Filbeck T, Roessler W, Knuechel R, et al. Clinical results of the transurethral resection and  
33  
34 13 evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after  
35  
36 14 intravesical instillation of 5-aminolevulinic acid. *J Endourol* 1999;13(2):117-21. doi:  
37  
38 15 10.1089/end.1999.13.117 [published Online First: 1999/04/23]  
39  
40  
41  
42  
43 16 44. Filbeck T, Pichlmeier U, Knuechel R, et al. Do patients profit from 5-aminolevulinic acid-induced  
44  
45 17 fluorescence diagnosis in transurethral resection of bladder carcinoma? *Urology*  
46  
47 18 2002;60(6):1025-8. [published Online First: 2002/12/12]  
48  
49  
50  
51 19 45. Ehsan A, Sommer F, Haupt G, et al. Significance of fluorescence cystoscopy for diagnosis of  
52  
53 20 superficial bladder cancer after intravesical instillation of delta aminolevulinic acid. *Urol Int*  
54  
55 21 2001;67(4):298-304. [published Online First: 2001/12/13]  
56  
57  
58  
59 22 46. De Dominicis C, Liberti M, Perugia G, et al. Role of 5-aminolevulinic acid in the diagnosis and  
60

- 1  
2  
3  
4 1 treatment of superficial bladder cancer: improvement in diagnostic sensitivity. *Urology*  
5  
6 2001;57(6):1059-62. [published Online First: 2001/05/30]  
7  
8  
9 3 47. D'Hallewin MA, Vanherzeele H, Baert L. Fluorescence detection of flat transitional cell carcinoma  
10  
11 after intravesical instillation of aminolevulinic acid. *American journal of clinical oncology*  
12 4  
13 1998;21(3):223-5. [published Online First: 1998/06/17]  
14 5  
15  
16 6 48. Cauberg EC, Kloen S, Visser M, et al. Narrow band imaging cystoscopy improves the detection of  
17 6  
18 non-muscle-invasive bladder cancer. *Urology* 2010;76(3):658-63. doi:  
19 7  
20 10.1016/j.urology.2009.11.075  
21 8  
22  
23 9 49. Burgues JP, Conde G, Oliva J, et al. [Hexaminolevulinate photodynamic diagnosis in non-muscle  
24 9  
25 invasive bladder cancer: experience of the BLUE group]. *Actas Urol Esp* 2011;35(8):439-45.  
26 10  
27 doi: 10.1016/j.acuro.2011.03.003 [published Online First: 2011/05/31]  
28 11  
29  
30 12 50. Kausch I, Sommerauer M, Montorsi F, et al. Photodynamic diagnosis in non-muscle-invasive  
31 12  
32 bladder cancer: a systematic review and cumulative analysis of prospective studies. *Eur Urol*  
33 13  
34 2010;57(4):595-606. doi: 10.1016/j.eururo.2009.11.041 [published Online First: 2009/12/17]  
35 14  
36  
37 15 51. Babjuk M, Soukup V, Petrik R, et al. 5-aminolaevulinic acid-induced fluorescence cystoscopy  
38 15  
39 during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.  
40 16  
41 *BJU Int* 2005;96(6):798-802. doi: 10.1111/j.1464-410X.2004.05715.x [published Online First:  
42 17  
43 2005/09/13]  
44 18  
45  
46 19 52. Gkritisios P, Hatzimouratidis K, Kazantzidis S, et al. Hexaminolevulinate-guided transurethral  
47 19  
48 resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a  
49 20  
50 2-year follow-up: a prospective randomized trial. *Int Urol Nephrol* 2014;46(5):927-33. doi:  
51 21  
52 10.1007/s11255-013-0603-z  
53 22  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 53. Mowatt G, N'Dow J, Vale L, et al. Photodynamic diagnosis of bladder cancer compared with white  
5  
6 2 light cystoscopy: Systematic review and meta-analysis. *Int J Technol Assess Health Care*  
7  
8  
9 3 2011;27(1):3-10. doi: 10.1017/S0266462310001364 [published Online First: 2011/01/26]  
10  
11  
12 4 54. Li K, Lin T, Fan X, et al. Diagnosis of narrow-band imaging in non-muscle-invasive bladder  
13  
14 5 cancer: a systematic review and meta-analysis. *Int J Urol* 2013;20(6):602-9. doi:  
15  
16 6 10.1111/j.1442-2042.2012.03211.x  
17  
18  
19 7 55. Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive  
20  
21 8 bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and  
22  
23 9 recurrence based on raw data. *Eur Urol* 2013;64(5):846-54. doi:  
24  
25 10 10.1016/j.eururo.2013.03.059  
26  
27  
28  
29  
30 11 56. Lee JY, Cho KS, Kang DH, et al. A network meta-analysis of therapeutic outcomes after new  
31  
32 12 image technology-assisted transurethral resection for non-muscle invasive bladder cancer:  
33  
34 13 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band  
35  
36 14 imaging. *BMC cancer* 2015;15:566. doi: 10.1186/s12885-015-1571-8  
37  
38  
39  
40 15  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **1 Figure legends**  
5

6 **2 Figure 1.** The PRISMA flow chart of included studies in DTA analysis.  
7

8  
9 **3 Figure 2.** The Forest Plot of estimates of DOR for NBI (A), HAL (C), 5-ALA (E) in lesion  
10  
11  
12  
13  
14 level and estimates of DOR for NBI (B), HAL (D), 5-ALA (F) in patient level.

15 **5 Figure 3.** The SROC curve for NBI, HAL and 5-ALA diagnosing NMIBC in lesion level (A)  
16  
17  
18  
19 and patient level (B).

20 **7 Figure 4.** Deeks' funnel plot with asymmetry test for NBI (A), HAL (B) and 5-ALA (C) in  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
8 lesion level.

1 **Table 1 Summary of the characteristics of the included studies**

Study	Institution No.	patients	Index test	period	Age, mean (range)	Male (%)	NMIBC (%)	Tumor lesions (n)
Shadpour et al.2016 <sup>31</sup>	Unicentre	50	NBI	2012-2013	63.86 ± 10.05	34(68.0)	100	95
Song et al.2016 <sup>29</sup>	Unicentre	63	NBI	2012-2013	66(56-76)	39(61.9)	94.1	21
Kobotake et Al.2015 <sup>36</sup>	Unicentre	135	NBI	2010-2014	75	110(81.5)	100	120
Ye et al.2015 <sup>11</sup>	Multicentre	384	NBI	NR	61(21-79)	267(69.5)	100	167
Shen et al.2012 <sup>30</sup>	Unicentre	78	NBI	2009-2010	68 (33–75)	62(79.5)	100	211
Zhu et al. 2012 <sup>26</sup>	Unicentre	12	NBI	2009-2010	57(28-73)	9(75.0)	100	9
Tatsugami et Al.2010 <sup>28</sup>	Unicentre	104	NBI	2007-2009	70.6 (38-90)	88(84.6)	NR	110
Cauberg et Al.2009 <sup>48</sup>	Multicentre	95	NBI	2007-2009	70.6 (38.1-90.2)	70(73.7)	NR	226
Herr et Al.2008 <sup>39</sup>	Unicentre	427	NBI	2007	65 (26-90)	316(74.0)	100	NR
Palou et Al.2014 <sup>34</sup>	Multicentre	283	HAL	2008-2009	67.5(42-95)	242(85.5)	94.1	621
Lapini et Al.2012 <sup>35</sup>	Multicentre	96	HAL	2010-2011	NR	80(83.3)	NR	108
Burgues et Al.2011 <sup>49</sup>	Multicentre	305	HAL	2006-2009	66.9(39-93)	270(88.5)	100	600
Ray et al.2010 <sup>15</sup>	Unicentre	27	HAL	2005-2006	70(49-82)	21(77.8)	100	NR
Schmidbauer et al.2009 <sup>32</sup>	Unicentre	66	HAL	NR	63(38-84)	49(74.2)	93.1	NR
Geavlete et Al.2008 <sup>41</sup>	Unicentre	128	HAL	2007-2008	65(36-81)	NR	92.2	NR
Fradet et Al.2006 <sup>42</sup>	Multicentre	298	HAL	NR	67±11	223(74.8)	100	113
Jichlinski et Al.2003 <sup>37</sup>	Multicentre	52	HAL	2000-2001	72±12	38(73.1)	100	143
Grimbergen et Al.2003 <sup>5</sup>	Unicentre	160	5-AL A	1998-2002	67(30-91)	NR	90.0%	390



1									
2									
3	Filbeck et	Unicentre	279	5-AL	1997-20	34-89	NR	90.3%	336
4	Al.2002 <sup>44</sup>			A	00				
5									
6	Dominicis et	Unicentre	49	5-AL	NR	60(31-77)	42(85.7)	100	52
7	Al.2001 <sup>46</sup>			A					
8									
9	Ehsan et	Unicentre	30	5-AL	NR	55-89	19(63.3)	NR	NR
10	Al.2001 <sup>45</sup>			A					
11									
12	Jeon at	Unicentre	62	5-AL	1997-19	61.9(32-80	57(91.1)	NR	148
13	Al.2001 <sup>38</sup>			A	99	)			
14									
15	Zaak et	Unicentre	605	5-AL	NR	65.6(16-99	472(78.0)	NR	552
16	Al.2001 <sup>27</sup>			A		)			
17									
18	Filbeck et	Unicentre	123	5-AL	1997	64.5(28-86	NR	91.9	124
19	Al.1999 <sup>43</sup>			A		)			
20									
21	Riedl et	Unicentre	52	5-AL	NR	44-79	NR	100	123
22	Al.1999 <sup>33</sup>			A					
23									
24	D'hallewin	Unicentre	16	5-AL	NR	NR	NR	100	50
25	et			A					
26	Al.1998 <sup>47</sup>								

1 WLC: white light cystoscopy; NT: new technology; 5-ALA: 5-aminolaevulinic acid; HAL:  
 2 hexylaminolevulinate; NBI: narrow band imaging; NR: not reported.  
 3




Figure 1. The PRISMA flow chart of included studies in DTA analysis.

177x108mm (300 x 300 DPI)




Figure 2. The Forest Plot of estimates of DOR for NBI (A), HAL (B), 5-ALA (C) in lesion level and estimates of DOR for NBI (D), HAL (E), 5-ALA (F) in patient level.

177x180mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3. The SROC curve for NBI, HAL and 5-ALA diagnosing NMIBC in lesion level (A) and patient level (B).

177x94mm (300 x 300 DPI)






Figure 4. Deeks' funnel plot with asymmetry test for NBI (A), HAL (B) and 5-ALA (C) in lesion level.

177x147mm (300 x 300 DPI)


## Supplementary Information



**Supplementary Figure 1.** The Forest Plot of study specific and pooled sensitivity (A) and specificity (B) for NBI in lesion level.




**Supplementary Figure 2.** The Forest Plot of study specific and pooled sensitivity (A) and specificity (B) for HAL in lesion level.




**Supplementary Figure 3.** The Forest Plot of study specific and pooled sensitivity (A) and specificity (B) for 5-ALA in lesion level.




A




B




C



Supplementary Figure 4. The Forest Plot of estimates of DOR for NBI (A), HAL (B) and 5-ALA (C) with low to moderate RoB in lesion level.



**Supplementary Figure 5.** The Forest Plot of estimates of DOR for NBI (A), HAL (B) and 5-ALA (C) with at least 100 patients in lesion level.



**Supplementary Figure 6.** Quality assessment of included studies. The distribution plot for risk of bias using QUADAS-2 tool. Studies are deemed to be at high, low or unclear risk of bias for each domain.

For peer review only

**Supplementary Table 1. Diagnostic performance results of individual studies for Meta-analysis**

Study ID	Patient-level analysis							Lesion-level analysis						
	Patient No.	SSY	SPY	FP R	FN R	PP V	NP V	Lesion No.	SSY	SPY	FPR	FN R	PP V	NP V
<b>NBI vs WLC</b>														
<b>Shadpour et al.2016<sup>1</sup></b>	50	NR	NR	NR	NR	NR	NR	175	69/80	70/85	15/85	11/80	69/84	74/75
<b>Song et al.2016<sup>2</sup></b>	63	16/16	46/47	1/47	0/1	16/16	23/23	66	19/19	45/47	2/47	0/1	19/21	7/7
<b>Kobota et al.2015<sup>3</sup></b>	135	NR	NR	NR	NR	NR	NR	379	78/84	227/263	36/63	6/8	78/14	203/203
<b>Ye et al.2015<sup>4</sup></b>	103	56/56	16/45	29/46	0/5	56/85	8/8	300	124/126	92/33	41/33	2/26	124/165	83/5
<b>Shen et al.2012<sup>5</sup></b>	78	47/47	9/22	13/22	0/4	47/47	7/7	309	160/160	98/34	36/34	0/60	160/196	72/2
<b>Zhu et al.2012<sup>6</sup></b>	12	NR	NR	NR	NR	NR	NR	31	4/6	19/22	3/22	2/6	4/7	20/20
<b>Tatsugami et al.2010<sup>7</sup></b>	104	NR	NR	NR	NR	NR	NR	313	55/63	156/203	47/203	8/6	55/102	144/144
<b>Cauberg et al.2009<sup>8</sup></b>	95	NR	NR	NR	NR	NR	NR	389	167/179	116/163	47/63	12/179	167/214	47/51
<b>Herr et al.2008<sup>9</sup></b>	427	90/90	311/324	13/24	0/0	90/103	265/265	NR	NR	NR	NR	NR	NR	NR
<b>HAL vs WLC</b>														
<b>Palou et al.2014<sup>10</sup></b>	283	NR	NR	NR	NR	NR	NR	149	379/2	820/416	128/948	37/416	379/507	699/702
<b>Lapini et al.2012<sup>11</sup></b>	96	NR	NR	NR	NR	NR	NR	234	82/83	101/126	25/26	1/8	82/107	80/81
<b>Burgues et al.2011<sup>12</sup></b>	305	NR	NR	NR	NR	NR	NR	165	404/9	900/1059	159/1059	7/41	404/563	863/863

1	<b>Ray et</b>	27	NR	NR	NR	NR	NR	NR	120	21/2	84/9	10/9	0/2	21/3	35/3
2	<b>al.2010<sup>1</sup></b>									1	4	4	1	1	5
3	<b>3</b>														
4	<b>Schmid</b>	66	52/5	2/8	6/8	0/5	52/5	3/3	364	109/	151/	50/2	4/1	109/	158/
5	<b>bauer</b>		2			2	8			113	201	01	13	159	158
6	<b>et</b>														
7	<b>al.2009<sup>1</sup></b>														
8	<b>4</b>														
9	<b>Geavlet</b>	128	NR	NR	NR	NR	NR	NR	243	87/9	56/1	47/1	6/9	87/1	76/8
10	<b>e et</b>									3	03	03	3	34	2
11	<b>al.2008<sup>1</sup></b>														
12	<b>5</b>														
13	<b>Fradet</b>	196	40/4	128/	10/1	8/4	40/5	106/	206	77/8	101/	11/11	6/8	77/8	63/7
14	<b>et</b>		8	138	38	8	0	113		3	112	2	3	8	1
15	<b>al.2006<sup>1</sup></b>														
16	<b>6</b>														
17	<b>Jichlins</b>	52	33/3	7/17	10/1	0/3	33/4	3/3	143	205/	269/	74/3	49/	205/	306/
18	<b>ki et</b>		3		7	3	3			254	343	43	254	279	314
19	<b>al.2003<sup>1</sup></b>														
20	<b>7</b>														
21	<b>5-ALA</b>														
22	<b>vs</b>														
23	<b>WLC</b>														
24	<b>Grimbe</b>	160	NR	NR	NR	NR	NR	NR	889	232/	409/	118/	12/	232/	248/
25	<b>rgen et</b>									244	527	527	244	350	257
26	<b>al.2003<sup>1</sup></b>														
27	<b>8</b>														
28	<b>Filbeck</b>	279	168/	93/1	9/10	0/1	168/	81/8	NR	NR	NR	NR	NR	NR	NR
29	<b>et</b>		168	02	2	68	177	1							
30	<b>al.2002<sup>1</sup></b>														
31	<b>9</b>														
32	<b>Domini</b>	49	NR	NR	NR	NR	NR	NR	179	2/9	84/1	43/1	7/9	2/45	80/8
33	<b>cis et</b>										27	27			0
34	<b>al.2001<sup>2</sup></b>														
35	<b>0</b>														
36	<b>Ehsan</b>	30	NR	NR	NR	NR	NR	NR	151	39/4	71/9	20/9	1/4	39/5	59/5
37	<b>et</b>									0	1	1	0	9	9
38	<b>al.2001<sup>2</sup></b>														
39	<b>1</b>														
40	<b>Jeon at</b>	62	NR	NR	NR	NR	NR	NR	257	71/7	69/1	57/1	3/7	71/1	54/5
41	<b>al.2001<sup>2</sup></b>									4	26	26	4	28	4
42	<b>2</b>														
43	<b>Zaak et</b>	605	288/	271/	189/	75/	288/	55/1	NR	NR	NR	NR	NR	NR	NR
44	<b>al.2001<sup>2</sup></b>		363	460	460	363	477	08							
45	<b>3</b>														
46	<b>Filbeck</b>	123	NR	NR	NR	NR	NR	NR	341	75/8	185/	38/2	5/8	75/1	78/7
47	<b>et</b>									0	223	23	0	13	8

1 **al.1999<sup>2</sup>**

2 4

3 **Riedl et** 52 26/2 10/1 8/18 0/2 26/3 6/6 NR NR NR NR NR NR NR

4 **al.1999<sup>2</sup>** 6 8 6 4

5 5

6 **D'Halle** 16 NR NR NR NR NR NR 113 11/1 27/6 36/6 3/1 11/4 34/3

7 **win et** 4 3 3 4 7 4

8 **al.1998<sup>2</sup>**

9 6

10

11

---

12 NMIBC: non-muscle-invasive bladder cancer; WLC: white light cystoscopy; 5-ALA: 5-aminolaevulinic  
 13 acid; HAL: hexylaminolevulinate; NBI: narrow band imaging; NT: new technology; SSY: sensitivity; SPY:  
 14 specificity; FPR: false positive rate; FNR: false negative rate; PPV: positive predictive value; NPV: negative  
 15 predictive value; NR: not reported.

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

**Supplementary Table2. Diagnostic performance results for sensitivity analysis of studies with low to moderate RoB and at least 100 patients at lesion level.**

	Low to moderate RoB			At least 100 patients		
	Median	Lower Quartile	Upper Quartile	Median	Lower Quartile	Upper Quartile
<b>NBI vs WLC (n=6)</b>	<b>NBI vs WLC (n=3)</b>					
Sensitivity	95.85	88.80	99.60	92.86	90.08	95.63
Specificity	74.99	71.66	80.98	76.85	73.01	81.58
Positive predictive value	79.84	75.87	82.02	68.42	61.17	71.79
Negative predictive value	99.33	97.90	100	100	98.82	100
False positive rate	25.01	19.02	28.34	23.15	18.42	26.99
False negative rate	4.15	0.40	11.20	7.14	4.37	9.92
<b>HAL vs WLC (n=6)</b>	<b>HAL vs WLC (n=4)</b>					
Sensitivity	95.00	92.97	98.21	92.19	91.48	92.97
Specificity	83.33	76.38	88.65	85.74	77.33	87.42
Positive predictive value	71.65	67.94	76.16	73.26	70.05	77.94
Negative predictive value	99.17	94.20	99.89	96.13	91.70	99.68
False positive rate	16.67	11.35	23.62	14.26	12.58	22.67
False negative rate	5.00	1.79	7.03	6.84	5.24	7.65
<b>5-ALA vs WLC (n=4)</b>	<b>5-ALA vs WLC (n=2)</b>					
Sensitivity	95.51	94.75	96.33	94.42	-	-
Specificity	77.82	71.90	79.26	80.28	-	-
Positive predictive value	66.19	63.44	66.31	66.33	-	-
Negative predictive value	100	99.12	100	98.25	-	-
False positive rate	22.18	20.74	28.10	19.72	-	-
False negative rate	4.49	3.67	5.25	5.58	-	-

NMIBC: non-muscle-invasive bladder cancer; WLC: white light cystoscopy; 5-ALA: 5-aminolaevulinic acid; HAL: hexylaminolevulinate; NBI: narrow band imaging; NR: not reported.

**Appendix: Full search strategy**

## 1. Searching in MEDLINE, Embase and CENTRAL

All databases were searched using both controlled vocabulary (namely MeSH in MEDLINE and Emtree in Embase) and a wide range of free-text terms

Search code for MEDLINE (accessed via PubMed) and CENTRAL

<b>Patients</b>		
Bladder cancer	#1	bladder neoplasms [MeSH] OR carcinoma OR tumor, urothelial cell [MeSH] OR transitional cell carcinoma*[tiab] OR bladder neoplasm*[tiab] OR bladder cancer[tiab] OR BCa[tiab]
<b>Index test</b>		
Photodynamic diagnosis	#2	“photodynamic diagnosis” [MeSH] OR “PDD” [tiab] OR “photodynamic” [tiab] OR hexaminolevulinate [tiab] OR HAL[tiab] OR “5-aminolevulinate acid”[tiab] OR 5-ALA[tiab] OR cystoscopic[tiab] OR cystoscopy
Narrow band imaging	#3	“narrow band imaging” [MeSH] OR NBI [tiab] OR cystoscopic[tiab] OR cystoscopy[tiab]
Cochrane Highly Sensitive Search Strategy	#4	(observational trial[Publication Type] OR diagnostic[Publication Type] OR detection[tiab] OR observational[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT humans[mh])
Search algorithm		#1 AND (#2 OR #3) AND #4

## 2. Searching other resources

Previous systematic reviews in the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effectiveness and the PROSPERO international prospective register of systematic reviews for completed or published systematic reviews



## References

1. Shadpour P, Emami M, Haghani S. A Comparison of the Progression and Recurrence Risk Index in Non-Muscle-Invasive Bladder Tumors Detected by Narrow-Band Imaging Versus White Light Cystoscopy, Based on the EORTC Scoring System. *Nephrourol Mon* 2016; 8(1):e33240.
2. Song PH, Cho S, Ko YH. Decision Based on Narrow Band Imaging Cystoscopy without a Referential Normal Standard Rather Increases Unnecessary Biopsy in Detection of Recurrent Bladder Urothelial Carcinoma Early after Intravesical Instillation. *Cancer Res Treat* 2016; 48(1):273-80.
3. Kobatake K, Mita K, Ohara S, et al. Advantage of transurethral resection with narrow band imaging for non-muscle invasive bladder cancer. *Oncol Lett* 2015; 10(2):1097-1102.
4. Ye Z, Hu J, Song X, et al. A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study. *Sci Rep* 2015; 5:10905.
5. Shen YJ, Zhu YP, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a "second look" matters? *Int Urol Nephrol* 2012; 44(2):451-7.
6. Zhu YP, Shen YJ, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of clinically unconfirmed positive urine cytology. *Urol Int* 2012; 88(1):84-7.
7. Tatsugami K, Kuroiwa K, Kamoto T, et al. Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. *J Endourol* 2010; 24(11):1807-11.
8. Cauberg EC, Kloen S, Visser M, et al. Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. *Urology* 2010; 76(3):658-63.
9. Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. *BJU Int* 2008; 102(9):1111-4.
10. Palou J, Hernandez C, Solsona E, et al. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study. *BJU Int* 2015; 116(1):37-43.
11. Lapini A, Minervini A, Masala A, et al. A comparison of hexaminolevulinate (Hexvix((R))) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study. *Surg Endosc* 2012; 26(12):3634-41.
12. Burgues JP, Conde G, Oliva J, et al. [Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group]. *Actas Urol Esp* 2011; 35(8):439-45.
13. Ray ER, Chatterton K, Khan MS, et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. *BJU Int* 2010; 105(6):789-94.
14. Schmidbauer J, Remzi M, Klatter T, et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. *Eur Urol* 2009; 56(6):914-9.
15. Geavlete B, Multescu R, Georgescu D, et al. Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors. *J Endourol* 2009; 23(6):977-81.
16. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. *J Urol* 2007; 178(1):68-73; discussion 73.
17. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. *J Urol* 2003; 170(1):226-9.
18. Grimbergen MCM, van Swol CFP, Jonges TGN, et al. Reduced Specificity of 5-ALA Induced Fluorescence in Photodynamic Diagnosis of Transitional Cell Carcinoma after Previous Intravesical Therapy. *European Urology* 2003; 44(1):51-56.
19. Filbeck T, Pichlmeier U, Knuechel R, et al. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? *Urology* 2002; 60(6):1025-8.

- 1 20. De Dominicis C, Liberti M, Perugia G, et al. Role of 5-aminolevulinic acid in the diagnosis and  
2 treatment of superficial bladder cancer: improvement in diagnostic sensitivity. *Urology* 2001;  
3 57(6):1059-62.
- 4 21. Ehsan A, Sommer F, Haupt G, et al. Significance of fluorescence cystoscopy for diagnosis of superficial  
5 bladder cancer after intravesical instillation of delta aminolevulinic acid. *Urol Int* 2001; 67(4):298-304.
- 6 22. Jeon SS, Kang I, Hong JH, et al. Diagnostic efficacy of fluorescence cystoscopy for detection of  
7 urothelial neoplasms. *J Endourol* 2001; 15(7):753-9.
- 8 23. Zaak D, Kriegmair M, Stepp H, et al. Endoscopic detection of transitional cell carcinoma with 5-  
9 aminolevulinic acid: results of 1012 fluorescence endoscopies. *Urology* 2001; 57(4):690-4.
- 10 24. Filbeck T, Roessler W, Knuechel R, et al. Clinical results of the transurethral resection and evaluation  
11 of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of  
12 5-aminolevulinic acid. *J Endourol* 1999; 13(2):117-21.
- 13 25. Riedl CR, Plas E, Pfluger H. Fluorescence detection of bladder tumors with 5-amino-levulinic acid. *J*  
14 *Endourol* 1999; 13(10):755-9.
- 15 26. D'Hallewin MA, Vanherzeele H, Baert L. Fluorescence detection of flat transitional cell carcinoma after  
16 intravesical instillation of aminolevulinic acid. *Am J Clin Oncol* 1998; 21(3):223-5.
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	Title page
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	None
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5-6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Appendix
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	Figure1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6-7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8



# PRISMA 2009 Checklist

Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	7-8
----------------------	----	---	-----

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6-7
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8-9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Supplementary Figure 6
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Supplementary Table 1
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	9-10
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	10
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10-12
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	12
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	12
<b>FUNDING</b>			



# PRISMA 2009 Checklist

Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	13-14
---------	----	--	-------

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only